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1. Introduction 
1.1. The right ventricle (RV) under pressure  
In recent years, earlier recognition and new treatment modalities have improved prognosis for 
patients with left heart failure. Unfortunately, still little is known about the cellular and 
molecular mechanisms that underlie right heart failure as well as therapeutic approaches. 
Moreover, the effects of current available treatments to improve the right heart function are not 
yet clear and more investigation in this respect is needed. 
1.1.1. Structure and function of the RV 
Left heart anatomy, function, and its response to acute cardiac events have been widely studied. 
Less is known about right heart development, physiology, and pathophysiology, and it remains 
relatively understudied. Right heart failure is substantially different from left heart failure due 
to their difference in anatomy and development [1]. First heart field (FHF) progenitor cells 
contribute exclusively to the development of the left ventricular (LV) myocardium while the 
second heart field (SHF) contributes to development of outflow tract and RV myocardium [2, 
3]. Therefore, the difference in cardiac progenitor cells of RV and LV myocytes may result in 
structural, functional and geometric differences between the RV and LV [4]. 
The RV wall is much thinner compared to the LV and its mass is 1/6th of that of the LV. The 
low volume to surface area ratio of the RV makes it a highly conformable chamber [4]. Sinus 
and cone are two anatomically and functionally different cavities in RV which generate and 
regulate systolic pressure respectively [4]. The RV and LV share a wall (septum) and share the 
pericardial space besides pericardial fibers [1]. The septum and RV wall have approximately 
an equal share in RV function [1]. Mammalian cardiomyocytes contain isoforms of β-myosin 
and α–myosin heavy chains mainly expressed in ventricles and atria, respectively, which in 
association with myosin light chains form a single hexameric unit [4]. The ventricles contract 
through interaction of myosin complexes with actin complexes.  
The RV is responsible for pumping the same stroke volume as the LV. However, the RV 
requires 25% of the stroke work of the LV due to lower pulmonary vasculature resistance that 
is 1/10th of the systemic vascular resistance. The RV delivers deoxygenated blood to the lungs 
for gas exchange and is structurally adapted for sustained low–pressure perfusion of the 
pulmonary circulation. Systolic pressures generated by the RV is dependent on the LV and right 
ventricular systolic pressure (RVSP) is greater when LV pressure is increased [4]. The RV has 
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no effect on the systolic pressure of the LV unless severe LV hypotension was present [4]. 
Altogether, the RV is dependent on the LV for at least a part of its contractility. 
1.1.2. Right ventricular hypertrophy (RVH), right heart failure and remodelling 
Our knowledge from left ventricular hypertrophy (LVH), failure, and remodelling can be 
partially helpful in recognition of RV failure (RVF) as both ventricles have different embryonic 
origins. RVF is a major determinant of morbidity and mortality in pulmonary vascular diseases 
such as acute pulmonary embolism and chronic pulmonary hypertension (PH). It is also a 
determinant in other non-pulmonary vasculopathies such as systemic hypertension [5, 6]. 
Right heart hypertrophy is divided into adaptive and maladaptive forms. Adaptive right heart 
hypertrophy is an adjustment of RV to increased afterload, leading to myocardial remodelling 
and concentric right heart hypertrophy. This situation is also called compensated right heart 
insufficiency with largely preserved right heart function. In contrast, the concept of maladaptive 
right heart hypertrophy reflects a lack of compensation for elevated right heart afterload by the 
right heart which results in eccentric hypertrophy. Eccentric maladaptive hypertrophy is 
accompanied by reduced right heart function and progressive symptoms of heart failure in 
decompensated RV insufficiency [7]. The mechanisms determining the transition between 
concentric and eccentric remodelling are still unclear.  
Despite an increase in compliance to accommodate an increased volume, the capacity of the 
RV to respond to chronic pressure overload is finite and the RV will develop muscle mass 
accumulation (hypertrophy). Adaptive alterations to increased afterload include elevation of 
intraluminal pressure and increased wall stress [6]. The intraluminal pressure elevation leads to 
increased oxygen consumption in heart with concomitantly reduced myocardial perfusion [6]. 
The increased wall stress can be counteracted with a reduction in the intraluminal diameter or 
thickening of the wall in order to maintain cardiac output (CO) [8]. This adaptive myocardial 
hypertrophy is mediated via strain sensitive ion channels and integrins in cardiac cells and is 
enhanced by autocrine, paracrine and neurohumoral influences [9]. This results in alterations at 
cellular level, formation of extracellular matrix (ECM), and the growth of vascular cells [9]. If 
these compensatory mechanisms are exceeded, contractile dysfunction, myocardial fibrosis, 
right ventricular dilatation and right heart failure occur. 
The transition from compensated to decompensated right heart failure is insufficiently 
characterized [5, 9]. At cellular level, increased pressure overload causes the myocyte damage 
or myocyte lost which results in remodelling as a compensatory response. In remodelling, the 
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cells undergo hypertrophy which includes increased size of cardiomyocytes, elevated protein 
synthesis, thickening of ventricular wall and increased cell contraction [10]. In left heart failure 
due to ischemia, increased diameter and length of cardiomyocytes as well as increased cross-
sectional area (CSA) of cells are reported [10]. Alteration in re-expression of fetal-type 
contraction genes, changes in cellular energetic and metabolic status, changes in expression 
and/or function of excitation-contraction (E-C) coupling proteins, and subsequently myocyte 
death are other alterations in cardiac remodelling [6, 11]. At the compensated stage, adenosine 
triphosphate (ATP) production can be maintained by increased glycolysis, whereas e.g. reactive 
oxygen species (ROS)-dependent signalling pathways are involved in the induction of protein 
synthesis and formation of hypertrophy. Furthermore, the low levels of mitochondrial ROS 
result in induction of hypoxia-inducible factor-1α (HIF-1α) and decreased ratio of glycolysis to 
glucose oxidation [12]. The activated HIF-1α increases the proangiogenetic factors and 
chemokines such as vascular endothelial growth factor (VEGF) and stromal-derived factor 1 
(SDF1) and subsequently increases the angiogenesis [12]. Upon transition to decompensated 
right heart failure, factors such as hypoxia, ROS and transcription factors, e.g., HIF-1α cause 
the mitochondrial dysfunction [12]. In more detail, elevated levels of mitochondrial ROS 
suppress the HIF-1α, reverse the glycolytic phenotype, and suppress the angiogenesis in the 
hypertrophied heart [12]. Respiratory capacity and complex V-dependent ATP production 
continue to fall. As a result of the decrease in mitochondrial glucose oxidation, the energy 
requirement cannot be covered despite increased glycolytic ATP production. This energy deficit 
has a direct effect on the systolic and diastolic function of the cardiomyocytes. The damage of 
the mitochondrial respiratory chain complexes, the resulting decrease in respiration and 
possibly a calcium overload of the mitochondria lead to a further massive ROS increase, which 
leads to an activation of apoptosis, necrosis and further damage to the mitochondria. In addition, 
impairment of the E-C coupling causes relaxation by an increase in the diastolic calcium 
concentration, while a possible decrease in the calcium peak in the systole can additionally 
reduce the contraction.  
Increased RV wall tension under pressure overload activates signalling cascades in RV 
promoting fibrosis accompanied by ECM synthesis and vascularization [9, 13]. The 
predominant increase of collagen in the ECM network will affect ventricular size and shape [9]. 
Increased RV fibrosis and matrix metalloproteinase (MMP) signalling leading to abnormal 
ECM degradation impairs cardiac function and may contribute to reduced ventricular 
compliance [9, 14]. The aberrant ECM degradation in decompensated heart hypertrophy is 
mediated by increased tumour necrosis factor-α (TNF-α) , chymase and tryptase secretion 
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leading to MMPs activation [9]. Furthermore, RV hypertrophy in rabbits is associated with 
increased collagen synthesis and diminished collagen degradation [15]. Moreover, increased 
fibrosis is found in pulmonary arterial hypertension (PAH) patients as well as in rats with right 
heart hypertrophy [9]. 
In the left heart, it is already shown that the contractile dysfunction is associated with alterations 
in contractile proteins, deficiency of E-C coupling, mitochondrial defects and a decrease in the 
phosphorylation potential of the ATP. Moreover, extracellular changes in the matrix and 
fibrosis formation, possibly triggered by hypoxia and enhanced by insufficient vascularization, 
contribute to the development of heart failure [5, 9]  
The mechanisms involved in cardiac hypertrophy lead to increased oxygen demand and 
promoted myocardial angiogenesis to maintain the contractile function. Thus, the interaction 
between cardiomyocytes and microvasculature plays an important role [16]. Improved 
ventricular function could be achieved by an increased capillary density in the RV by Iloprost 
administration.[17]. Iloprost is a synthetic analogue of prostaglandin I2 (PGI2) that dilates 
systemic and pulmonary arterial vascular beds. Furthermore, the role of ischemia in progressive 
right heart failure is evident by stress-induced angina, decreased systolic epicardial blood flow 
and diminished myocardial perfusion in PH patients [18-20]. Lack of angiogenesis plays a 
central role in transition from compensated to decompensated left heart failure [21]. 
Furthermore, a mismatch between the number of capillaries and size of cardiomyocytes in left 
heart may cause myocardial hypoxia, cardiac contractile dysfunction, apoptosis and cardiac 
hypertrophy [9]. This mismatch during LV hypertension resulted in transition from adaptive 
hypertrophy to heart failure, but little is known about the role of angiogenesis in RVH [9]. In 
the transverse aortic constriction (TAC) animal model for pressure overload-induced cardiac 
hypertrophy and heart failure, the number of microvessels per myocytes was initially increased, 
but, then declined [9]. Monocrotaline (MCT)-induced PH is accompanied by reduced capillary 
density in the RV of rats in contrast to the chronic hypoxia (CH)-induced PH model in rats [22]. 
In this model, it has been shown that angiogenesis is dependent on the expression of the VEGF 
[22].  
Understanding the pathways involved in cardiac remodelling as well as gaining insight into the 
relationship between remodelling and heart failure progression might result in developing novel 
therapeutic targets. 
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1.1.3. Oxidative and nitrosative stress in cardiac hypertrophy and failure  
ROS such as superoxide (O2
•-) and the hydroxyl radical (•OH) or other non-radical oxidative 
agents such as hydrogen peroxide (H2O2) are detrimental to proteins, lipids, and DNA. Damage 
can lead to deterioration of cellular functions. Reactive nitrogen species (RNS) are molecules 
derived from nitric oxide (NO-) and O2
•-, e.g. produced by the inducible nitric oxide synthase 2 
(NOS2) and the nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) oxidase, 
respectively. RNS act in combination with reactive ROS to damage cells. 
Potential sources of ROS inside the cell include NADPH oxidases (NOX 1-5 and Doux 1-2), 
cyclooxygenases, xanthine oxidases, cytochrome P450 enzymes, lipoxygenases, NO synthases 
and mitochondria [23-27]. In mitochondria, complex I and complex III of electron transport 
chain (ETC) are known the main sources of ROS generation via “ electron leakage” during 
respiration [26, 28-31]. Impaired mitochondrial function is associated with increased ROS 
generation that impairs tricarboxylic acid (TCA) cycle and ETC complexes and subsequently 
disturbs mitochondrial ATP production. Mitochondrial respiratory chain complexes, xanthine 
oxidases, the uncoupled NO synthase, monoamine oxidases (MAO) and NADPH oxidases are 
the major known sources of ROS in left heart hypertrophy and heart failure [26].     
Besides detrimental effects of ROS, a wide range of physiological roles in biological processes 
including intracellular homeostasis, adaptation to cellular stress such as hypoxia as well as 
autophagy and immune regulation are proposed to them [32, 33]. However their effect seems 
to be concentration dependent, as excessive ROS can cause deleterious effects by 
overwhelming antioxidant defences resulting in pathologies such as development of heart 
failure.  
With regard to their function in the heart, ROS and RNS are involved in redox signalling and 
contribute to cardiac contraction, hypertrophy, and cardiac disease. ROS activate several 
enzyme/gene cascades in cardiac disorders. Protein kinases B (PKB) and C (PKC) and mitogen-
activated protein kinases (MAPKs) such as extracellular signal–regulated kinase (ERK), p38- 
MAPK, nuclear factor-kappa B (NF-κB), and c-Jun N-terminal kinase (JNK) are redox-
modulated proteins and they play an important role in left heart failure [25, 26]. ROS in high 
concentration induce apoptosis and necrosis of myocytes via p38- MAPK and JNK [34]. 
Moreover, the level of oxidative stress-induced apoptosis in cardiomyocytes appears to be 
dependent upon the level of ROS produced [27]. In other words, level of ROS is a determinant 
of myocyte phenotype via activation and interplay of multiple kinase signalling pathways 
including JNK, ERK1/2 and PKB which reflect pro-apoptotic or anti-apoptotic effects [27]. 
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ROS lead to cardiomyocyte hypertrophy via one of the main molecular mechanisms which is 
thioredoxin 1 (Trx1)-sensitive oxidation of G protein Ras [26]. NOS particularly NOS3 is a 
source of ROS in regard to RVH [35]. NOS3 uncoupling occurs in myocardium exposed to 
chronic pressure load, and this serves as a major source for myocardial ROS, which is linked to 
dilative hypertrophy remodelling [35]. Furthermore, increased NOX2 expression and activation 
is demonstrated during chronic cardiac hypertrophy and in cardiac biopsies from patients with 
left heart failure [26]. Increased generation of ROS and RNS induces contractile dysfunction 
via suppression of enzymes responsible for E-C coupling as well as polynitrosylation of the 
ryanodine receptor (RyR) [9].  
In the RV, increased mitochondrial complex II expression and ROS generation are observed in 
MCT-induced PAH rats compared to control group [36]. Furthermore, generation of extra 
mitochondrial- and mitochondrial-ROS is increased in the severely hypertrophied RV of PAH 
rats [37]. Sutendra et al showed that transition from compensated RVH to maladaptive RVH is 
accompanied by an increase in mitochondrial ROS leading to HIF-1α inhibition and attenuation 
of angiogenesis [12]. Furthermore, mitochondrial NOX4–derived ROS generation and 
mitochondrial dysfunction is implicated in autophagy and results in remodelling of the RV and 
LV in murine model of right heart hypertrophy [38]. Therefore, addressing increased ROS 
production could be a therapeutic target in the treatment of cardiac hypertrophy and heart failure 
[39-41].  
1.1.4. Animal models to study RVH 
Various species ranging from mice to primates has been utilized as models of RVH to study 
anatomic, pathophysiologic and molecular adaptations of right heart to increased pressure. 
Most models used for RVH are rodents, particularly mice. Despite the increased costs and 
effort, large animal models are still used as they provide us with additional insight that can not 
be gained from rodent models due to significant differences between mice and humans in terms 
of heart rate (HR), oxygen consumption, contractile protein expression and response to loss of 
regulatory proteins. Animal models can provide insights about the determinants of right 
ventricular dysfunction, biomarkers and molecular patterns associated with RVH.  
Hypoxia-induced RVH 
Chronic exposure of animals to hypoxia is the most common PH model resulting in pulmonary 
vasoconstriction, with subsequent vascular remodelling which in turn will culminate in the 
development of PH as well as right heart hypertrophy. This model has greatly contributed to 
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understanding the molecular processes involved in the vascular remodelling induced by chronic 
pulmonary disease and oxygen deprivation. CH can be induced by exposing animals 
normobaric or hypobaric hypoxia [42]. CH model is used in a wide variety of animals including 
mice, rats, guinea pigs, dogs, cows, pigs and sheep [43, 44]. This classic model produces PH 
with some variability across species. For example, the degree of hypoxia-induced PH developed 
in mice is rather modest as compared to bovines [45]. CH is characterized by mostly mild-to-
moderate pulmonary vascular and RV remodelling [42, 46]. Therefore, this model is only 
partially suited to investigate the mechanisms of human PH [44]. 
MCT-induced RVH 
The MCT model is another classical PH model currently used in rats by oral administration of 
monocrotaline phytotoxin [43]. Two weeks after MCT administration, progressive remodelling 
of the pulmonary vasculature occurs which results in elevated pulmonary vascular resistance 
(PVR), PH development and finally RV hypertrophy and failure. The MCT model has 
contributed to an improved understanding of vascular remodelling in PH and serves as a model 
system for severe PH [47]. This model has been particularly beneficial in investigating the role 
of lung injury and chronic inflammation in pulmonary vascular diseases [47]. The complex 
obliterative lesions found in human patients with severe PAH do not develop in this rodent 
model [47]. 
Additional advantages of the MCT PH model are its technical simplicity, reproducibility, and 
low cost compared with other models [47]. Furthermore, the investigation of functional, 
structural, and molecular changes accompanied with RV compensated hypertrophy and RVF 
will be possible in this model [48-52]. This model allows precise measurements of CO besides 
right ventricular and central pulmonary arterial compliance [45]. The bigger size of rat plays a 
role in more precise measurement of cardiac factors. Interestingly, MCT has been found to be 
ineffective in mice [45]. 
Pulmonary artery banding (PAB) 
In our study, PAB model in mice is used to investigate the RVH due to increased afterload. The 
surgical technique of PAB was first described by Muller and Dammann in 1952 as a model of 
pressure-induced RVH and RVF [44, 53]. The PAB model is induced by putting a constricting 
band or clip around pulmonary artery/trunk. Clinically it is used as a temporary surgical 
palliation to prevent excessive pulmonary blood flow in congenital cardiac defects with large 
left-to-right shunts [54]. RV strain due to pulmonary artery/trunk stenosis in PAB results 
initially in compensated hypertrophy. If untreated, RV will progress to decompensated 
hypertrophy and right-sided heart failure. Therefore, the PAB model is ideally suited to 
Introduction 
 
26 
  
investigate mechanisms underlying the progression from compensated to decompensated RVH. 
Pressure-induced right heart strain resulting in significant RVH is the central feature of the PAB 
model [45]. Unfortunately, the high operative mortality rate associated with this model is a 
disadvantage of this model. Given the technical difficulty of the surgery itself prohibits PAB 
from being a more common model for right heart failure studies [53]. The extremely thin fragile 
wall of the pulmonary trunk and the inability of the RV to withstand stress while the pulmonary 
artery is being manipulated are the challenges while performing this operation [53]. Because of 
low blood pressure in the RV any dissection underneath the pulmonary trunk using forceps may 
lead to blockage of blood flow to the lungs and consequently results in immediate respiratory 
and cardiac distress [53]. In CH and MCT models, the effect of increased afterload cannot be 
discriminated from the impact of hypoxia and / or MCT treatment. In line with this, MCT has 
been shown to induce myocarditis in rats complicating thus the study of the RV hypertrophy 
and failure [55]. In PAB model, right heart hypertrophy can be examined as a primary disease 
and not as secondary symptom of PH, which can be seen in the CH and MCT models [56]. 
1.2. Pulmonary hypertension (PH) 
1.2.1. PH definition and classification  
PH is the leading cause of RVH and RVF. It is a complex and multifactorial disease caused by 
functional and structural changes in the pulmonary vasculature. PH is characterised by vascular 
constriction leading to elevated pulmonary arterial resistance, vascular remodelling, RVH, and 
ultimately RVF. It is defined by elevated resting mean pulmonary artery pressure (MPAP) 
which is equal or more than 25 mmHg measured by right heart catheterization (RHC) [57, 58]. 
PH is classified by etiology, which was last revised in 2013 [59, 60]. PH is divided into five 
main subtypes according to pathological, pathophysiological and therapeutic characteristics: 1) 
PAH; 2) PH due to left heart disease; 3) PH  associated with respiratory system disorders and/or 
hypoxia ; 4) chronic thromboembolic PH (CTEPH) or embolic PH; and 5) PH with unclear 
and/or multifactorial mechanisms [60, 61] (Table 1). PAH is a rapidly progressing disease with 
mortality rate of 20-40% at 3 years after diagnosis [9].  
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Table 1. Clinical classification of pulmonary hypertension, Nice, France, 2013[60] 
1. PAH 
1.1. Idiopathic PAH 
1.2. Heritable PAH 
1.2.1. BMPR2 
1.2.2. ALK-1, ENG, SMAD9, CAV1, KCNK3 
1.2.3. Unknown 
1.3. Drug and toxin induced 
1.4. PAH associated with 
1.4.1. Connective tissue diseases 
1.4.2. HIV infection 
1.4.3. Portal hypertension 
1.4.4. Congenital heart diseases 
1.4.5. Schistosomiasis 
1'. Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
 1". Persistent pulmonary hypertension of the newborn (PPHN) 
2. PH due to left heart disease 
2.1. Left ventricular systolic dysfunction 
2.2. Left ventricular diastolic dysfunction 
2.3. Valvular heart disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital 
cardiomyopathies 
3. PH due to lung diseases and/or hypoxia 
3.1. Chronic obstructive pulmonary disease (COPD) 
3.2. Interstitial lung disease 
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4. Sleep-disordered breathing 
3.5. Alveolar hypoventilation disorders 
3.6. Chronic exposure to high altitude 
3.7.  Developmental lung diseases 
4. CTEPH 
5. PH with unclear multifactorial mechanisms  
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5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, 
splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders  
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH 
 
*5th WSPH Nice 2013. Main modifications to the previous Dana Point classification are 
in bold. BMPR2 = bone morphogenic protein receptor type II; CAV1 = caveolin-1; ENG 
= endoglin; HIV = human immunodeficiency virus; PAH =pulmonary arterial 
hypertension. 
 
1.2.2. Pathophysiology of PH 
The pathophysiology of PH is complex and multifactorial. Different pathobiological features 
characterize the clinical PH groups [62]. 
PAH (group 1) is caused by increased PVR. Vasoconstriction, obstructive remodelling of the 
pulmonary vessel wall, inflammation and thrombosis are the main factors responsible for the 
elevated resistance of the pulmonary circulation.  All cell types of the pulmonary arterial vessel 
are affected in PAH. Furthermore, the release of cytokines and chemokines from activated 
endothelial cells mediates the influx of inflammatory cells such as monocytes, T or B 
lymphocytes contributing to pulmonary artery smooth muscle cell (PASMC) proliferation [63].  
In PH due to left heart disease (group 2), elevated left atrial pressure induces reactive PH. 
Chronic left heart failure may be due to systolic or diastolic cardiac dysfunction or due to 
valvular diseases [64].  
PH due to lung disease and/or hypoxia (group 3) is characterized by multiple mechanisms 
including hypoxic vasoconstriction, mechanical stress of hyperinflated lungs, loss of capillaries, 
inflammation as well as toxic effects of inhalative agents e.g. cigarette smoke [65]. 
CTEPH (group 4) is induced by failure to resolve acute emboli that later undergoes fibrosis 
resulting in mechanical obstruction of the pulmonary arteries. Abnormalities in platelet function 
or in the coagulation cascade may cause or aggravate the initial thrombosis and provoke a 
chronic obstruction of the vascular bed [66].  
Group 5 consists of several forms of PH with an unclear or multifactorial etiology as well as 
heterogenic pathophysiology. Various pathologies such as hematological disorders, systemic 
disorders, metabolic disorders or patients with chronic renal failure are grouped in this category 
[67].  
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1.2.3. Diagnosis and treatment of PH 
RHC is the gold standard in the diagnosis of PH, allowing for measurement of pulmonary artery 
pressure and CO [4, 57, 59]. Transthoracic echocardiography is the main non-invasive 
diagnostic tool to evaluate PH and its severity. Brain natriuretic peptide (BNP) and troponins 
are two biomarkers that are frequently elevated in PH due to myocardial stretch and ischemia. 
These biomarkers can be used to evaluate severity in PH, but they are not sensitive and specific 
for diagnosis alone [68, 69]. Magnetic resonance imaging (MRI) is utilized to assess RV mass, 
RV volume and RV ejection fraction (EF) in PH associated with RV failure [14]. 
Current available treatments for most forms of PH only attenuate the progression of PH, with 
an overall poor diagnosis with lung or combined heart-lung transplant being the only 
therapeutic options. Supportive treatments include anticoagulation, diuretics and oxygen (O2) 
therapy [59]. Pharmacologic treatments targeting some of the underlying molecular pathways 
in PH include soluble guanylate cyclase (SGC)-stimulators, prostacyclin derivatives, endothelin 
receptor antagonist and phosphodiesterase 5 inhibitors [4, 9, 59, 70, 71].  
RV adaptation to PH determines the clinical prognosis. Although there are numerous 
therapeutic options for left ventricular failure (LVF), only a few specific interventions to 
support RV function and prevent right heart failure are currently available. These interventions 
are mostly indirect and non-selective. A poor understanding of the underlying pathophysiology 
of RVH and RVF results in scarce pharmacologic treatment options [4, 5]. Available treatments 
for RVF in PH are diuretics and continuous intravenous inotrope infusion [5].  
Novel therapies for the pulmonary vasculature and RV in PH are aimed to target mitochondria, 
for example Archer et al showed that inhibition of the pyruvate dehydrogenase kinase (PDK) 
by dichloroacetate (DCA) partially reverts RVH by restoring mitochondrial membrane 
potential (Δψm) and improving glucose oxidation [72] . Another emerging concept to treat RV 
failure is to inhibit mitochondrial fission and promote mitochondrial fusion [73]. 
1.3. Mitochondria and the heart 
Mitochondria are the power plant of the cell and play an important role in ATP production, 
ROS production and detoxification, metabolism, apoptosis, and cellular Ca2+ homeostasis [74, 
75]. As mitochondria occupy at least 30% of the cardiac cell volume, mitochondrial dynamics 
are a particular focus in cardiac research. 
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1.3.1. Role of mitochondria in heart function and heart failure 
Myocardial mitochondria play a central role in cellular energy production, generation and 
scavenging of ROS, intracellular calcium ([Ca2+]i) homeostasis, and regulation of apoptosis and 
growth [76]. Mitochondrial dysfunction may result in maladaptive right ventricular remodelling 
and transition from compensated to decompensated right heart failure. Conversely, healthy 
mitochondria may support adaptive remodelling and function of the RV. 
An increasing number of studies are focusing on right heart dysfunction and its related 
mitochondrial abnormalities. In regard to mitochondrial metabolic alterations, reduced glucose 
oxidation and increased glycolysis are found in MCT-induced RVH in rats [72]. Moreover, 
Fang et al have shown increased RV fatty acid (FA) oxidation and reduced glucose oxidation 
in rats exposed to PAB operation [77]. Dysfunctional RVH in hypoxia-induced right heart 
hypertrophy model in rats is characterized by a gene expression profile compatible with 
impairment of FA and glucose oxidation [78]. Elevation of glycolysis-related genes expression 
and higher PDK-mediated glycolytic shift were observed in two rat models of RVH [72, 79]. 
In early stages of hypertrophy in dogs and rats, FA metabolism is compromised [80]. 
Conversely, no significant decline in FA oxidation could be detected in mild and compensated 
hypertrophy induced by suprarenal aortic banding in rats [80]. This is in line with a finding in 
a canine model of coronary microembolization-induced heart failure in which no decrease in 
FA oxidation was observed during compensated stage compared to healthy animals [81]. 
Additionally, in compensated hypertrophy induced by abdominal aortic constriction in rats, 
glycolysis was modestly increased with unchanged glucose oxidation [82]. Moreover, 
following aortic constriction in rats, cardiac glucose oxidation tended to increase initially, but, 
was unchanged in the phase of compensated hypertrophy and decreased when systolic 
dysfunction occurred [82]. These findings suggest the decreased mitochondrial ATP production 
in advanced LVF. A reduction in total and mitochondrial creatine kinase activity, a slight 
decrease in ATP concentration and a significant decrease of creatine and phosphocreatine 
occurred during the transition from compensated to decompensated heart failure [83, 84].  This 
reduced energy reserve may contribute to the progression of heart failure, although it is still a 
question whether it is sufficient to be a primary divert of heart failure [85]. Also, in 
hypertrophied isolated perfused RVs from ferrets a decreased phosphocreatine and creatine 
content as well as a decreased creatine kinase activity were observed while ATP level was 
unchanged. The ATP content could be maintained by enhanced glycolysis [86]. In patients with 
precapillary PH, elevated myocardial glucose uptake and shift of FA oxidation to glucose 
oxidation were seen in the development of cardiac hypertrophy [87]. Moreover, a shift towards 
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elevated FA oxidation and glycolysis associated with RVF is reported in PH patients [88]. 
Furthermore, a lower FA oxidation with restricted RV function was observed in PH patients 
[89].  
Decreased mitochondrial capacity for oxygen consumption and oxidative phosphorylation are 
observed in MCT-induced right heart hypertrophied rats which highlight the alteration of 
mitochondrial energy-producing ability in RVF [90]. Reduced mitochondrial respiration at 
complex I of the ETC is observed in rats with hypoxia-induced right heart hypertrophy which 
had dysfunction of RV [78]. In a rat model of CH-induced heart hypertrophy; mitochondrial 
respiration was compromised in the LV within 24 h of hypoxic exposure and remained reduced 
afterward while it was unaffected in the RV [91]. Moreover elevated mitochondrial respiration 
via an increase in number of mitochondria was detected in hypoxia-induced RVH model in rats 
[92, 93]. In the neonatal rabbit model of thoracic aortic banding-induced pressure overload 
hypertrophy, activity of complex I and III of the mitochondrial respiratory chain is reduced 
during compensated hypertrophy, which was associated with diminished ROS and oxidative 
damage at the phase of transition to heart failure [94]. 
These studies suggest that the RV is also subjected to metabolic remodelling during the 
formation of hypertrophy, with various findings depicting that hypertrophy of the right heart is 
partially different from that of the left heart. The inhibition of mitochondrial respiration could 
be compensated in the short term by increased glycolytic ATP production. This compensation 
thus contributes as an adaptive mechanism to maintain the RV function. However, since the 
glycolytic ATP production is less efficient than the oxidative ATP production and also it leads 
to lactic acidosis, it may not be able to compensate for the increased energy requirement in the 
case of progressive hypertrophy in the long term. This hypothesis is supported by the finding 
that an increase in mitochondrial metabolism by DCA leads to an improvement in right 
ventricular function [72]. In the stage of compensated cardiac insufficiency the diminished 
mitochondrial ATP production can be compensated by an increased glycolytic activity [80]. 
The RV undergoes a metabolic remodelling and alteration in mitochondria biogenesis and 
function during hypertrophy. It is still debateable whether these changes are secondary effects 
in heart failure or if the primary mitochondrial alterations lead to heart failure. The role of 
structural and functional changes of mitochondrial respiratory chain complexes, mitochondrial 
membrane proteins, and proteins involved in ROS and calcium homeostasis specifically in the 
transition from compensated to decompensated right heart failure need to be further explored.  
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1.3.1.1. Mitochondrial ROS in right heart hypertrophy 
ROS can be generated during oxidative phosphorylation in the mitochondria as a by-product of 
normal aerobic metabolism [95]. Therefore, the main process by which the heart generates 
energy can lead to ROS production. ROS are the possible mediators of cardiac hypertrophy and 
contractile dysfunction. Interactions of ROS with E-C coupling pathways e.g. polynitrosylation 
of RyRs can cause functional impairment of the myocardium. In addition, ROS induce necrosis 
and apoptosis in higher concentrations via p38-MAPK and JNK [34]. The involvement of 
superoxides in myocardial hypoxia is also probable as superoxides are able to limit NO 
mediated vasodilation [96] . Characteristically, left heart failure is associated with excessive 
ROS production and lack of detoxification mechanisms. A down-regulation of peroxisome 
proliferator-activated receptor-alpha (PPAR-α) and mitochondrial superoxide dismutase (SOD) 
is involved in this process [97]. High ROS level results in generation of nitrotyrosine residues 
in tissue inhibitor of metalloproteinases and liberation of active MMPs which induce RV 
remodelling and fibrosis in a model of PAB [38]. Moreover, histological analysis of collagen 
content in RVs from PAB-induced right heart hypertrophy in mice demonstrated a significant 
increase of ROS in comparison with control mice [38]. An increased ROS production by 
complex II of the mitochondrial respiratory chain in conjunction with increased HIF-1α 
expression and activation of the p38-MAPK was responsible for the transition from 
compensated to decompensated right heart failure [27, 98]. The antioxidant EUK-1340, a 
superoxide dismutase superoxide and catalase mimetic, reduced myocardial hypertrophy and 
fibrosis in MCT-induced PAH in rats [99]. 
In connection with the increased pressure load of the RV, NO synthases, in particular NOS3, 
must be also considered as a source for ROS. The mechanical and oxidative stress under the 
increased afterload leads to the decoupling of the NO synthases during the formation of 
hypertrophy. In this state, the NO synthases provide a non-inconsiderable contribution to the 
ROS production and, apart from the formation of myocardial hypertrophy, are involved in a 
negative functional and structural remodelling. In addition, a down-regulation of their reducing 
co-factor tetrahydrobiopterin (BH4) in the pressure-loaded heart supports decoupling and thus 
accelerates the further production of radicals [35].  
1.3.2. Mitofusin-2 and mitochondrial homeostasis in heart 
Mitofusin-2 (MFN2) is a protein responsible for rearrangement of the outer mitochondrial 
membrane (OMM). This large GTPase is an essential mediator of mitochondrial fusion, a 
critical process of mitochondrial homeostasis [73, 100]. It is strongly expressed in heart tissue 
and its deficiency is associated with disturbance of the mitochondrial network in cultured 
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neonatal cardiomyocytes promoting early apoptosis in cells [101]. In addition to its localization 
in the mitochondria, large amounts of MFN2 are located on endoplasmic reticulum (ER) 
membranes where it facilitates the transfer of Ca2+ from the ER into the adjacent mitochondria, 
subsequently exposing mitochondria to very high local Ca2+ concentrations [100, 101]. High 
expression of MFN2 in the myocardium confirms its crucial role in ER-mitochondrial coupling 
in the heart. Ablation of MFN2 results in a change of the ER structure and ER fragmentation 
[100]. Cells lacking MFN2 have slower Ca2+ release from the ER associated with decreased 
mitochondrial Ca2+ uptake [100]. Pressure-induced hypertrophy in left heart caused 
downregulation of MFN2 in a compensatory mechanism mediated by peroxisome proliferator-
activated receptor-delta (PPAR-δ) and PPAR-gamma coactivator-1 beta (PPARGC-1β) [100].  
1.3.3. Mitochondrial uncoupling proteins (UCPs) 
1.3.3.1. Definition, distribution and function of UCPs 
Uncoupling proteins are a subfamily of the mitochondrial anion carrier protein family located 
in inner mitochondrial membrane (IMM) [102, 103]. Five isoforms of uncoupling proteins have 
been discovered thus far. UCPs contain six α-helical hydrophobic transmembrane domains by 
which they are inserted into the mitochondrial membrane. UCPs are proteins that uncouple 
oxygen consumption from oxidative phosphorylation (i.e. ATP production) [104] by catalysing 
proton transport across the inner membrane, thereby dissipating the proton electrochemical 
gradient built up by the respiratory chain [102]. UCP activity might be regulated by superoxide 
or ROS products [103]. UCPs might be protective against ROS and attenuate or prevent 
oxidative damage by decreasing the reduced state of the mitochondrial respiratory chain [102, 
105]. Although the exact physiological/pathological functions of UCPs are still not fully 
understood, a few molecular functions are suggested for these proteins. 
The best-characterized UCP to date, UCP1 is a 33-kDa tissue specific protein exclusively found 
in brown adipose tissue (BAT) of hibernators, small mammals and new-borns of large 
mammals. UCP1 is present in large number in the mitochondria and is required for cold-induced 
non-shivering thermogenesis in mammals [103, 105]. As the activity of an individual UCP1 is 
low, a large number of UCP1 complexes are required to ensure fast and complete uncoupling 
of respiration in order for thermogenesis [106]. This protein increases BAT respiration rate in 
response to hormonal stimuli by sustaining a free FA-induced purine nucleotide (PN)–inhibited 
H+ conductance [102, 105, 107]. The sympathetic nervous system is a major factor for UCP1 
activation [106]. 
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UCP2 and UCP3 are uncoupling proteins identified following UCP1 on the basis of their 
sequence similarity [107]. The mild-uncoupling hypothesis states that these two proteins are 
activated under specific stress situations to ameliorate the superoxide production [105, 106, 
108]. They do not play a role in cold-induced thermogenesis and keep the Δψm at a low level in 
order to minimise ROS production [104, 105]. ROS production is higher in UCP2 or UCP3 
knockout mice [106]. UCP2 and UCP3 may also be involved in the regulation of the resting 
metabolic rate as a basal proton leak in the IMM is associated with the resting metabolic rate 
[106].  
UCP2 mRNA is detected in several cell types and tissues for example macrophages, 
lymphocytes, pulmonary cells, liver, spleen, brain, kidney, heart, digestive tracts and muscles 
[105, 106, 109]. Stress conditions stimulate UCP2 expression in certain areas of the brain and 
the liver [105] .The distribution of the UCP2 protein in the heart is controversially discussed 
[110]. UCP2 shares 72% of the amino acid sequence with UCP1 [106]. UCP2 mRNA levels 
are much higher than the actual protein [103]. The reason for this discrepancy might be related 
to 5´ non-coding region of mRNA that contains an additional open reading frame [103, 111]. 
The UCP2 gene is located on chromosome 11 in humans and chromosome 7 in mice, close to 
a region that has been linked to obesity and diabetes [109]. UCP2 is not very stable with a half-
life of approximately 30 minutes [110, 112]. 
Very little is known about the physiological/pathological roles of UCP2 and its regulation 
despite its ubiquitous distribution. It should also be mentioned that the exact functions of UCP2 
are not yet clearly understood. UCP2 may mediate proton leak across the IMM into the matrix 
and therefore decrease the Δψm [110, 113, 114]. As a mild uncoupler of oxidative 
phosphorylation (OX-PHOS), UCP2 may play a role in reduced mitochondrial-derived ROS 
production [35, 114-116]. Moreover, UCP2 seems to be involved in a “metabolic switch” 
described as compensatory increased FA entry into TCA cycle which occurs as a result of 
reduced/inhibited pyruvate entry. Furthermore, UCP2 probably is a sensor for the substrates 
entering the TCA cycle and may function as a carrier exporting pyruvate out of the 
mitochondrial matrix. This proposed function is consistent with increased FA oxidation and 
limited glycolysis –derived pyruvate utilization during starvation [108]. Of note, the Δψm can 
interfere with UCP2 function by limiting pyruvate export in case of insufficient mitochondrial 
polarization [108]. UCP2 operates cooperatively or sequentially with additional Ca2+ transport 
modulators and mechanisms across the IMM, as ATP-dependent inhibition of mitochondrial 
Ca2+ uptake is mediated via UCP2 [117]. Additionally, UCP2 is shown to play a role for 
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efficient mitochondrial oxidation of glutamine, an alternative fuel for the respiratory chain in 
absence of glucose, in human hepatocarcinoma cells [118]. In summary, UCP2 may influence 
mitochondrial respiration by decreasing Δψm, regulate ROS, act as a calcium modulator, and 
negatively regulate pyruvate uptake into mitochondria thereby enhancing FA oxidation [119]. 
Suppression of UCP2 with antisense oligonucleotides increased Δψm and O2•- production in 
murine endothelial cells [3]. Interestingly, O2•- and products of lipid peroxidation activate 
UCP2. This highlights the potential role of UCP2 to be an effective regulator of O2•- production 
in mitochondria [120]. Genipin, a highly selective inhibitor of UCP2, increases Δψm and ATP 
levels via inhibition of proton leak [121]. Surprisingly, a loss of function of UCP2 in fibroblasts 
did not cause a significant increase in ROS production [111] which underscores the cell specific 
function of UCP2. In this murine model, the presence of UCP2 caused a decline in Δψm, raised 
the respiration rate and reduced the sensitivity to uncouplers [111]. UCP2 is associated with 
decreased intracellular ROS concentration and resistance to degenerative processes [106]. 
UCP2 and UCP3 are shown to cooperatively play a role in mitochondrial Ca2+ uptake when 
highly expressed [122]. In this study, knock-down of UCP2 and UCP3 was neither additive nor 
synergistic in Ca2+ uptake [122]. 
UCP3 is also tissue specific and its mRNA is found predominantly in skeletal muscles of 
humans and rodents as well as BAT, white adipose tissue and heart of mice [102, 109, 123]. 
Traces of UCP3 are also detected in human heart [109]. UCP3 has 73% amino acid sequence 
homology with UCP2. UCP3 is involved in control of substrate utilization such as FAs without 
being a transporter of FA itself [105]. However, some studies show its role as a FA exporter 
outside of mitochondrial matrix [106]. 
So far, UCP4 and UCP5 are not characterized. UCP4 is a putative mitochondrial carrier that is 
more distant from other UCPs and is discovered in brain and UCP5 or brain mitochondrial 
carrier protein (BMCP1) is also found in brain [102, 106]. 
1.3.4. Mitochondrial coupling in right heart hypertrophy 
Hyperpolarization of the Δψm in right heart hypertrophy appears to correlate with the 
development of hypertrophy [124].  A reduction of the mitochondrial proton leak has been 
observed in hypoxia-induced RVH [86, 92]. Hyperpolarization could serve as an adaptive 
mechanism for more efficient energy production in cardiac hypertrophy. However, how Δψm is 
augmented and how this affects mitochondrial ROS production is still unclear. Moreover, 
studies in a compensated LVH canine model induced by ischemia and re-perfusion injury did 
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not show a loss of Δψm [125]. In hypertrophied RVs of rats exposed to hypobaric hypoxia, 
mitochondrial O2 consumption is raised despite of decreased mitochondrial  proton leak which 
is associated with  induction of transcript levels of a few genes including cytochrome c oxidase 
subunit II (COXII)  and UCP2 as well as reduction of UCP3 [92]. 
1.4. Calcium homeostasis in cardiac physiology and pathology 
1.4.1. Calcium dynamics in the heart 
Calcium as a second messenger is the major regulator of a number of various cellular functions 
such as stimulation of ATP production, E-C coupling and muscle contraction. E-C coupling is 
one of the fundamental properties of cardiomyocytes which turns the electrical excitation of the 
cardiomyocytes into contraction of the heart. Tight regulation of [Ca2+]i concentration and Ca
2+ 
signalling in cardiac tissue is crucial, as phasic high amplitude Ca2+ transients govern 
contractions in the heart. 
Subcellular mechanisms contribute to the transition from the resting state to contraction. During 
the cardiac action potential, depolarization of the cell membrane of the myocyte via Ca2+-
induced Ca2+ release (CICR) occurs. The membrane depolarization during the action potential 
opens sarcolemmal voltage-gated L-type calcium channels (LTCCs) and results in influx of low 
amounts of Ca2+ into the myocyte, triggering a large-scale Ca2+ release via stimulated RyRs 
which are Ca2+ release channels of the sarcoplasmic reticulum (SR). This increase of calcium 
termed "calcium spark" followed by binding of the released calcium to troponin C regulatory 
protein within the myofilaments activates the contractile machinery [126]. 
Heart relaxation is triggered by a decrease of cytosolic Ca2+ concentration. This process is 
initiated by dissociation of Ca2+ from troponin C. Its re-uptake to the SR is mediated by the 
sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) as well as Ca2+ removal from the 
sarcolemma by Na+-Ca2+ exchanger (NCX) , albeit to a lesser extent [127-129]. As this is an 
energy-intensive process requiring high amount of ATP, the heart is one of the most 
mitochondrial-rich organs with mitochondria occupying approximately 30% of the volume of 
ventricular myocytes [100]. 
1.4.2. Regulatory components of mitochondrial calcium signalling  
Defective EC-coupling in heart failure may be the result of an altered amount or function of 
proteins relevant for calcium homeostasis. The characterization of those alterations is a 
prerequisite for understanding the pathophysiology of myocardial failure and for the 
Introduction 
 
37 
  
development of new strategies to treat patients with heart failure. An overview of the major 
channels, transporters and proteins associated with calcium homeostasis in myocytes are shown 
in the figure 1. 
 
Figure 1. Cardiac cellular Ca2+ handling and Ca2+-dependent signalling in adult 
ventricular cardiomyocyte  
Intracellular Ca2+ ([Ca2+]i) is regulated by Ca
2+ flux into the cytoplasm and via different 
transporters and channels: Ca2+ enters the myocyte through the L-type Ca2+ channel (LTCC), 
and activates the ryanodine receptor (RyR) to release Ca2+ from the sarcoplasmic reticulum 
(SR). The Ca2+ released from the internal stores, paired with Ca2+ entering through LTCC 
causes a rise in intracellular free Ca2+ that can bind to troponin C (that resides in myofilaments) 
to cause contraction. Ca2+ is then extruded from the cell via the Na+-Ca2+ exchanger (NCX) or 
taken up by the SR via the sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a). Na+-H+ 
exchanger (NHX) regulates the intracellular pH and transcellular Na+ absorption. Na+-K+-
ATPase pumps Na+ out of the cell while K+ is pumped in. Calcium enters the mitochondria 
primarily through the mitochondrial Ca2+ uniporter (MCU). Mitochondrial permeability 
transition pore (mPTP) increases the permeability of the mitochondrial membranes to 
molecules of less than 1500 Daltons in molecular weight. 
 
In order for Ca2+ to enter the mitochondria, it diffuses freely through the highly permeable 
OMM. In order to enter the matrix, Ca2+ must pass through the IMM which is essentially 
impermeable to Ca2+. There are three mechanisms for Ca2+ entry into mitochondria which the 
mitochondrial Ca2+ uniporter (MCU) is perhaps the most important one [130]. The MCU is an 
ion channel with high conductance and selectivity which drives the short term and massive 
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entry of Ca2+ ions into mitochondria [131]. Rapid mode of Ca2+ uptake (RaM) and 
mitochondrial RyR1 are the two other mechanisms responsible for Ca2+ entry into mitochondria 
[132, 133]. Three Ca2+ efflux pathways are also identified including the mitochondrial NCX, 
H+-Ca2+ exchanger (HCX) and the mitochondrial permeability transition pore (mPTP). 
1.4.2.1. Three crucial regulators of cardiac contractility 
SERCA is one of the main Ca2+ regulatory proteins. SERCA is encoded by three genes 
SERCA1, SERCA2 and SERCA3 [127, 134]. SERCA2a is an isoform predominantly expressed 
in cardiac and slow twitch skeletal muscle [127, 134, 135]. SERCA2a mRNA and protein level 
in heart muscle and slow twitch skeletal muscle is 10- to 50-fold higher than its level in smooth 
muscle and non-muscle tissue [134]. SERCA2a is critical for cardiac development [135]. 
SERCA2a elevates myocyte relaxation by decreasing cytosolic Ca2+ concentration and active 
Ca2+ transport thus replenishing the [Ca2+]i stores which subsequently provides Ca
2+ for the next 
contraction [128]. SERCA2a is responsible for transporting two Ca2+ ions per every molecule 
of hydrolyzed high energy phosphate against the high ion gradient between the free [Ca2+]i (100 
nM-1 µM) and free Ca2+ in the SR (~1 mM) [127].  
Phospholamban (PLB) is a small transmembrane protein expressed in cardiac and slow twitch 
skeletal muscle.This protein is located in the SR and plays an important role in calcium 
signalling of myocytes. It is one of the main mediators of the interaction between the β-
adrenergic signalling pathway leading to protein phosphorylation and the Ca2+ signalling 
pathway leading to muscle contraction [129]. Stimulation of β-adrenergic signalling causes 
increased concentration of cyclic adenosine monophosphate (cAMP) and subsequent 
phosphorylation of PLB either by protein kinase A (PKA) or Ca2+-calmodulin-dependent 
protein kinase II (CaMKII) [136]. PLB modulates SERCA2a by inhibiting the activity of 
SERCA2a and SR Ca2+ transport in its non-phosphorylated form, whereas phosphorylation of 
PLB at either Ser16 by PKA or Thr17 by CaMKII results in disruption of the ATPase-PLB 
interaction and removal of its inhibitory effects on SERCA2a which consequently accelerates 
Ca2+ uptake by the SR [127, 128, 136]. PLB can be dephosphorylated by protein phosphatases 
(PPs) including phosphatase type 1 (PP1) and type 2A (PP2A) in cardiomyocytes [126]. PP1 
seems to have higher affinity to PLB [126]. PKA and CaMKII are also able to phosphorylate 
LTCC and RyR channels and thus regulate cardiac Ca2+cycling [126]. 
The NCX plays the most dominant role in myocardial calcium efflux. The NCX in its forward-
mode is responsible for extrusion of one Ca2+ ion for three Na+ ions [127, 137]. NCX is a 
voltage-dependent  protein and can operate in reverse-mode at low stimulation frequencies or 
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during the action potential, promoting Ca2+ influx and prolongation of the Ca2+ transients in 
order to increase E-C coupling [127, 137]. 
1.4.3. Calcium signalling and ROS 
Calcium interacts with other pathways including ROS. Interactions among ROS and calcium 
signalling can be considered as bidirectional, in which ROS can regulate cellular calcium 
signalling and calcium signalling is essential for ROS generation. Elevated levels of Ca2+ 
activate ROS-production which results in formation of free radicals. Because Ca2+ uptake leads 
to mild uncoupling of mitochondria and dissipation of the Δψm, some of its effects on ROS 
generation may be due to this uncoupling effect [138]. The mechanism by which uncouplers 
enhance ROS generation is still under debate, but probably involves perturbation of the pH 
gradient across the mitochondrial membrane, which affects the topology of H2O2 generation 
[138].  
Several calcium transporters or proteins which are localized in plasma membrane, can be 
regulated by ROS. In ventricular cardiomyocytes isolated from guinea pig, exogenous ROS 
suppressed L-type Ca2+ current irreversibly [139]. Moreover, ROS increased the [Ca2+]i by 
stimulation of SR Ca2+ release via RyR channels and activation of Ca2+ entry via the reverse-
mode of NCX in permeabilized rat ventricular myocytes [140]. In canine model of chronic heart 
failure, the ROS generated in the failing heart led to modification of RyR2 and its subsequent 
abnormal activity [141]. Furthermore, reduced cytosolic Ca2+ transients , elevated SR Ca2+ leak 
and reduced [Ca2+]SR are demonstrated in this study [141]. Additionally, in Langendorff 
perfused rat hearts mild oxidative stress enhanced the Ca2+ response of RyR2 channels to 
cytoplasmic Ca2+ and this process was mediated by NOX2 [142]. In cardiomyocytes, 
mitochondria-derived ROS have been found necessary to maintain spontaneous RyR2-
mediated Ca2+ spark activity while excessive mitochondrial ROS production exerted a 
bidirectional regulation of Ca2+  spark activity in a dose-and time- dependent fashion supporting 
a mitochondrial control of SR Ca2+ release [143]. In rat cardiomyocytes, stretch-induced NOX2-
dependent ROS production in the sarcolemmal and t-tubule membranes sensitized the nearby 
RyR2 in the SR and triggered a burst of Ca2+ sparks, resulting in the induction of 
arrhythmogenic Ca2+ waves [144].  
1.4.4. Calcium signalling and heart failure 
Increasing evidences point to altered Ca2+ homeostasis as a highly relevant pathomechanism of 
heart failure characterized by abnormal contraction and relaxation as well as insufficient SR 
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Ca2+ uptake. Alterations in calcium signalling mostly occur due to disturbed function of the SR 
associated with impaired SR calcium content and subsequent prolongation of calcium 
transients. SR Ca2+ content reflects the balance between Ca2+ uptake and Ca2+ efflux. 
Diminished SR calcium content and its subsequent reduced systolic Ca2+ release from the SR 
as well as elevated diastolic Ca2+ concentrations in myocytes are well-known characteristics of 
heart failure [100, 145].  
Several studies focused on components regulating Ca2+ dynamics as well as the expression and 
function of these components in cardiac pathologies. Alterations in Ca2+ uptake into the SR in 
left heart failure resulting in decreased Ca2+ concentration in the SR have been ascribed to 
decreased SERCA2a production, reduced levels of PLB phosphorylation and increased Ca2+ 
depletion of the SR via leaky RyR channels [11, 100]. These events tend to shift Ca2+ out of the 
cell and reduce SR Ca2+ content. Moreover, decreased expression and activity of SERCA2a is 
reported in the failing left heart in animal studies [128, 146]. Furthermore, reduced SERCA2a 
expression and function is known as a main parameter leading to diminished Ca2+ accumulation 
in the SR associated with disturbed systolic and diastolic function in isolated myocytes from 
failing left human hearts [147]. In the failing human heart, a decline of the PLB mRNA level 
was consistently observed, while no difference was found between the failing and non-failing 
left heart in PLB protein level [127, 148]. However, selective enhancement of PLB 
phosphorylation is beneficial for treatment of left heart failure [126]. Moreover, a partial or 
total lack of phosphorylation of PLB disturbed SR Ca2+ uptake and resulted in dilated 
cardiomyopathy and heart failure [126]. Also, improved SR Ca2+ cycling linked to left heart 
function and remodelling in animal models of heart failure occurred by transfer of gene 
encoding SERCA2a, production of a constitutively phosphorylated PLB, and deletion/ablation 
of gene encoding PLB [11, 100, 128, 145, 147]. Interestingly, increased SERCA2a protein 
expression and preserved SR Ca2+ loading were also observed in RV of post- myocardial 
infarction (-MI) rats which suggested SERCA2a may play a role in the preservation of RV 
function in post-MI rat model [149]. Decreased SR Ca2+ uptake in the LV and increased SR 
Ca2+ uptake in the RV were reported in the left heart failure in MI rats which depicted the 
different SR remodelling of the SR membrane with regard to Ca2+ pump mechanisms [150]. 
Accelerated NCX forward-mode activity resulting in declined SR Ca2+ content and systolic SR 
Ca2+ release is described in a canine model of left heart failure [151]. In transgenic mice 
overexpressing NCX, reverse-mode NCX resulted in accelerated Ca2+ storage of the SR [137]. 
Elevated NCX activity/expression in left heart failure and hypertrophy may compensate for 
depressed sarcoplasmic reticular Ca2+ uptake, provide inotropic support through reverse-mode 
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Ca2+ entry, and/or deplete [Ca2+]i stores. Hasenfuss et al have shown that the expression of NCX 
mRNA and protein have been changed in failing left human heart [127]. Fang et al have 
demonstrated that MFN2 expression was downregulated in hypertrophied left hearts of rats and 
this downregulation was dependent on the etiology and time course of hypertrophy [152]. 
Moreover, MFN2 was reported as a main protein in modulating angiotensin-II-induced 
hypertrophy in neonatal rat cardiomyocytes and its upregulation inhibited the hypertrophy of 
these cells [153]. Moreover, human gene studies have detected the mutations of a few calcium 
cycling components in cardiomyopathies [154]. 
Other regulatory factors of [Ca2+]i cycling also play important roles in cardiac failure. Although 
in most of left heart failures the density of LTCCs seems to be either unchanged or reduced, 
alteration in its function is demonstrated in studies [155, 156]. Functional defect in LTCC [157], 
the increase in the space between LTCC and RyR [158], and abnormality in the channel-gating 
property of RyR [159, 160] are the factors which resulted in reduced E-C coupling in left heart. 
Dysfunction of RyR including changes in its properties or its sensitivity to activation by L-type 
Ca2+ current may contribute to calcium handling alteration in left heart failure [161]. Altered 
phosphorylation levels of three [Ca2+] i regulators PLB, LTCC and RyR in myocytes are shown 
in left heart hypertrophy and left heart failure [126]. It is proposed that, Phosphorylation of RyR 
channels by PKA or CaMKII causes leakage of Ca2+ from SR and induces Ca2+ handling 
dysregulation in myocardium and finally decline of left heart contractility [11]. In a study of 
MI model, CaMKII inhibition could prevent the progression of adverse cardiac remodelling 
[126].  
In failing right heart, the alteration of these Ca2+ signalling components at mRNA and protein 
level, their function and abnormalities, as well as their contribution to development of right 
heart hypertrophy and its progression to right heart failure are not yet well clarified. To 
determine how these components influence the SR Ca2+ content, Ca2+ cycling as well as 
cardiomyocyte contractility and to clarify the underlying mechanisms, more investigation is 
needed. Moreover, although there are a limited number of key players among these regulatory 
components, they are subject to numerous levels of regulation and cross talk. Characterization 
of these regulations and interactions will need further investigations.
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2. Aim of the study 
There is still hardly proven therapeutic option for right heart hypertrophy which allows the 
simultaneous treatment and decompensation of right heart failure. Recently, major attention is 
paid to target the mitochondrial dynamics in heart failure etiology, diagnosis and treatment. 
Elucidating the functional and cellular effects of mitochondrial interventions on the 
development of cardiac hypertrophy and failure can help us to understand the underlying 
mechanisms. As failing myocardium upon pressure overload faces significant alterations in 
energy metabolism and from the other hand UCP2 is a critical protein in modulating energy 
metabolism, we hypothesized that UCP2 could contribute to the etiology of right heart 
hypertrophy. Also, based on critical functions of balanced calcium homeostasis in normal heart 
physiology the maintenance of calcium balance is central to cardiac contractility and function. 
So, assuming the imbalanced cardiac calcium haemostasis as one of the main problems in 
cardiac hypertrophy and failure made us interested in focusing on this topic. 
In the present study a few main questions are going to be answered: 
 Does UCP2 play a role in the pathogenesis of right heart hypertrophy? 
 Which severities of right heart hypertrophy do the UCP2-/- mice develop?  
 What are the functional characteristics of UCP2-/- mice after PAB operation in vivo and 
in vitro? 
 What is the probable role of UCP2 in association with PAB operation in development 
of RVH? 
 What are the probable effects of UCP2 in association with PAB operation in isolated 
cardiomyocytes with special focus on ROS and Ca2+ signalling regulatory components? 
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Figure 2. Effect of pulmonary artery banding (PAB) on calcium regulatory proteins in 
the cardiomyocytes  
Does pulmonary artery banding (PAB) affect the calcium regulatory proteins; 
sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA2a) and phospholamban (PLB) at 
cardiomyocyte level? Is PAB in UCP2-/- cardiomyocytes associated with alterations in calcium 
cycling? Does knockout of UCP2 (UCP2-/-) affect the contractility of cardiomyocytes? Do PAB 
and UCP2-/- interact with ROS to play their role? 
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3. Materials and methods 
3.1. Materials 
3.1.1. Experimental animals 
Adult male homozygous UCP2-/- mice (B6.129S4-Ucp2tm1Lowl/J) were purchased from Jackson 
Laboratory (Bar Harbor, USA) and bred up to the 6th generation in our facilities. Male 
C57BL/6J mice bought from Charles River Laboratories (Sulzfeld, Germany) were used as wild 
type (WT) animals. 
All mice used in the experiments had a weight of 22 to 28 gram each. During the experimental 
period, the animals were housed in the animal facility of the Excellence Cluster of Cardio-
Pulmonary System (ECCPS) Institute of the Justus-Liebig University of Giessen.  
3.1.2. Regional council’s approvals for animal experiments 
All animal experiments were performed according to the regulations of the regional authorities 
and ethics committees for animal research. Approval numbers are mentioned below: 
GI 20/10 Nr. 86/2011 
„ Rechtsherzhypertrophie- Rolle verschiedener ROS-Produzenten bei ihrer Entstehung“ 
GI 20/10 Nr. 40/2012 
„ Rechtsherzhypertrophie und Mitochondrien “ 
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3.1.3. Mouse model of PAB, echocardiography and hemodynamic measurements 
Table 2. Substances and solutions 
Substance Trade name/ Description Company 
Buprenorphine 
hydrochloride 
Temgesic® Essex Pharma GmbH, 
Munich, Germany 
50% 2-Propanol/1% 
Povidone iodine-solution 
Braunoderm® B. Braun Melsungen AG, 
Melsungen, Germany 
Glucose 5% Glucose 20%® 
Diluted 1:4 
B. Braun Melsungen AG, 
Melsungen, Germany 
Heparin Heparin-Natrium-25000® Ratiopharm GmbH, 
Ulm, Germany 
Isoflurane Isoflurane Baxter® Baxter Deutschland GmbH, 
Unterschleißheim, Germany 
Ketamine hydrochloride  
(100 mg/ml) 
Ketamin 10%® bela-pharm GmbH & Co, 
Vechta, Germany 
Lidocaine hydrochloride Xylocaine Jelly 2% Astra Zeneca,  
Wedel, Germany 
Potassium chloride (KCl) 30 mg/ml KCl Carl Roth GmbH & Co, 
Karlsruhe, Germany 
Physiological saline solution  DeltaSelect GmbH, 
Dreieich, Germany 
Sodium chloride (NaCl) 
solution 
Isotonic NaCl solution  
0.9% ® 
B. Braun Melsungen AG, 
Melsungen, Germany 
NaCl solution 
(1000 ml) 
for flushing and washing B. Braun Melsungen AG, 
Melsungen, Germany 
Ventilation gas 
100% O2 
 Air Liquid, 
Siegen, Germany 
Xylazine hydrochloride Xylazin 2% Ceva Tiergesundheit GmbH, 
Düsseldorf, Germany 
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Table 3. Consumables 
Article Trade name/ Description Company 
Cannula 
24G (0,55 mm x 25 mm) 
26G (0,45 mm x 25 mm) 
30G (0,3 mm x 25 mm) 
BD Microlance 3® Becton Dickinson, 
Heidelberg, Germany 
Depilatory cream Veet® Veet, 
Heidelberg, Germany 
Dexpanthen ophtalmic 
ointment 
Bepanthen® eye and nasal 
ointment 
Bayer Vital, 
Leverkusen, Germany 
Embedding cassette, 
small size 
Rotilabo®-embedding 
cassette Macro 
Carl Roth GmbH & Co, 
Karlsruhe, Germany 
Embedding cassette,  
big size 
Tissue-Tek® Uni-Cassette® Sakura Finetek Europe, 
Zoeterwoude, Netherlands 
Falcon tube 
15 ml, 50 ml 
Cellstar® Tubes Greiner Bio-One GmbH, 
Frickenhausen, Germany 
IV Catheter, 
14G x 2", 20G x 1¼" 
Vasofix® Safety B. Braun Melsungen AG, 
Melsungen, Germany 
Medical adhesive band Durapore® 3M, 
St. Paul, USA 
Parafilm  American National Can Co, 
Menasha, USA 
Scalpel Feather® Disposal Scalpel Pfm Medical AG, 
Cologne, Germany 
Eppendorf tube 1,5 ml & 2 ml tube Sarstedt AG & Co, 
Nümbrecht, Germany 
Single use nitrile glove Peha soft® Nitrile Paul Hartmann AG, 
Heidenheim, Germany 
Single use glove Vasco® Nitril White B. Braun Melsungen AG, 
Melsungen, Germany 
Single use syringe, 
1 ml, 2 ml, 5 ml, 10 ml, 
20 ml 
Inject Luer® B. Braun Melsungen AG, 
Melsungen, Germany 
Single use syringe, 
50 ml 
Original Perfusor® syringe B. Braun Melsungen AG, 
Melsungen, Germany 
Three way stopcock 
 
Discofix® B. Braun Melsungen AG, 
Melsungen, Germany 
Cannula 
20G (0,9 mm x 40 mm) 
24G (0,55 mm x 2 mm) 
26G (0,45 mm x 25 mm) 
30G (0,3 mm x 25 mm) 
BD Microlance 3® Becton Dickinson, 
Heidelberg, Germany 
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Table 4. Equipment 
Equipment Trade name/ Description Company 
Anesthesia chamber  Von Keutz Labortechnik, 
Reiskirchen, Germany 
Cannula for flushing 
 
 Hugo Sachs Elektronik -
Harvard Apparatus GmbH, 
March, Germany 
Caliper ABSOLUTE digimatic 
caliper 
Mitutoyo Deutschland 
GmbH, 
Neuss, Germany 
Catheter for carotid artery Micro Cannulation System FST GmbH, 
Heidelberg, Germany 
Catheter for jugular vein Hyman Mouse Pressure 
Catheter (14 cm) 
NuMED Inc, 
Hopkinton, USA 
Light source KL-200 Fiber Optic 
Illuminator Light Source 
Leica Microsystems, 
Nussloch, Germany 
Pressure converter  Combitrans Monitoring Set  
Mod. II for arterial blood 
pressure measurement 
B. Braun Melsungen AG, 
Melsungen, Germany 
Pressure transducer APT300 Hugo Sachs Elektronik -
Harvard Apparatus GmbH, 
March, Germany 
Retractors Self-made from cannula 20G 
BD Microlance 3® 
 
Software HSE-HA-PULMODYN W-
for hemodynamic 
Hugo Sachs Elektronik- 
Harvard Apparatus GmbH, 
March, Germany 
Stereomicroscope Leica MS5 Leica Microsystems, 
Nussloch, Germany 
Stylet (for intubation) Self-made from spinal 
cannula 20G (0.9 mm x 75 
mm) 
B. Braun Melsungen AG, 
Melsungen, Germany 
Tracheal tube Self-made from Vasofix® 
Safety 20G IV Catheter, 
shortened to 1.5cm 
B. Braun Melsungen AG, 
Melsungen, Germany 
Tripod For holding syringes while 
flushing procedure 
 
Ventilator MiniVent Type 845 Hugo Sachs Elektronik -
Harvard Apparatus GmbH, 
March, Germany 
Water bath  Von Keutz Labortechnik, 
Reiskirchen, Germany 
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Table 5. Surgical instruments, needles and sutures 
Article 
Number 
Company Article description 
11009-13 FST Semken forceps: Curved, Serrated tips, 1.3 mm x 1 mm tip 
dimensions 
11050-10 FST Graefe forceps: Straight, Serrated tips, 0.8 mm x 0.7 mm tip 
dimensions 
11052-10 FST Graefe forceps: Curved, Serrated tips, 0.8 mm x 0.7 mm tip 
dimensions 
11370-31 FST Moria MC 31 Iris forceps: Curved, Serrated tips, 0.5 mm x 0.4 
mm tip dimensions 
12060-01 FST Castroviejo Micro needle holder: Straight, Slightly blunted 
tips, with lock 
14106-09 FST Fine scissor: Straight, Large finger loops, Sharp tips 
15003-08 FST Vannas-Tübingen Spring scissor: Sharp, 5 mm cutting edge 
15024-10 FST Spring scissor: Straight, Sharp tips, 8 mm cutting edge 
18025-10 FST Suture Tying forceps: Straight, Smooth tips 
304000 Becton 
Dickinson 
BD MicrolanceTM 3 disposable hypodermic needles, 20G x 
1½", 0.9 x 40 mm, yellow 
303800 Becton 
Dickinson 
BD MicrolanceTM 3 disposable hypodermic needles, 26G x ½", 
0.45 x 13 mm, brown 
30200 Becton 
Dickinson 
BD MicrolanceTM 3 disposable hypodermic needles, 27G x ¾", 
0.40 x 19 mm, grey 
304000 Becton 
Dickinson 
BD Microlance TM 3 disposable hypodermic needles, 30G x 
½", 0.30 x 13 mm, yellow 
4268113S-01 B. Braun 
Melsungen 
Vasofix® Safety 20G x 1¼", 1.1 x 33 mm, safety intravenous 
catheter with injection port 
4268210S-01 B. Braun 
Melsungen 
Vasofix® Safety 14G x 2", 2.2 x 50 mm, safety intravenous 
catheter with injection port 
523735 Teleflex 
Medical 
Weck hemoclip® Traditional, titanium ligating clip 
8728810F B. Braun 
Melsungen 
Perfusor® syringe 50 ml 
BC313R Aesculap Standard scissors – Blunt 
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EH7228 Ethicon 6-0 Prolene, C-1 13 mm 3/8c, polypropylene, blue monofil 
suture, non resorbable 
FD562R Aesculap Aesculap® Biemer clip , vascular clip, jaw opening 5 mm, jaw 
length 9 mm, closing force 20-25G 
 Edward 
Weck 
Clip applier 
 Ethicon Surgical threads non-absorbable ETHIBOND EXCEL®, 
size 5-0 
 
Table 6. Echocardiography devices 
Device Trade name/ Description Company 
Isoflurane vaporizer VetEquip KF Technology 
Rom, Italy 
Rectal thermometer  Indus Instruments 
Houston, USA 
Software Vevo® LAB- for analyzing 
ultrasound and 
photoacoustic data 
VisualSonics Inc. 
Toronto, Canada 
Ultrasound platform Vevo® 2100 - High-
Frequency Imaging 
Platform  
VisualSonics Inc. 
Toronto, Canada 
Ultrasound gel Aquagel® Parker Laboratories Inc. 
Fairfield, USA 
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3.1.4. Histology and stereology 
Table 7. Substances and solutions 
Article Trade name/ Description Company 
Acetic acid 100%  Merck KGaA, 
Darmstadt, Germany 
4′,6-Diamidino-2-
Phenylindole 
Dihydrochloride 
fluorescent stain Sigma-Aldrich, 
Steinheim, Germany 
Ethanol 
70%, 96%, 99.6% 
denatured with methyl-ethyl 
ketone 
 Fischer, 
Saarbrücken, Germany 
Isolectin B4-TRITC Lectin from Bandeiraea 
simplicifolia 
Sigma-Aldrich, 
Steinheim, Germany 
Isopropanol 99.8%  Fluka Chemie, 
Buchs, Switzerland 
Mounting medium Dako fluorescence mounting 
medium  
Dako Deutschland GmbH, 
Hamburg, Germany 
Mounting medium Pertex®- Xylene-soluble MEDITE GmbH, 
Burgdorf, Germany 
Picric acid aqueous, saturated AppliChem GmbH, 
Darmstadt, Germany 
Proteinase K  BIOZOL Diagnostica 
Vertrieb 
GmbH, Eching, Germany 
Sirius Red F3B  Niepötter Labortechnik, 
Bürstadt, Deutschland 
NaCl  Carl Roth GmbH, 
Karlsruhe, Germany 
Trizma® base  Sigma-Aldrich, 
Steinheim, Germany 
WGA lectin (-FITC) Lectin from Triticum 
vulgaris conjugated to 
fluorescein isothiocyanate 
Sigma-Aldrich, 
Steinheim, Germany 
 Xylol  Carl Roth GmbH, 
Krlsruhe, Germany 
 
 
 
 
 
Materials and methods 
 
51 
  
Table 8. Consumables 
Article Trade name/ Description Company 
Coverslip 24 x 36 mm  R. Langenbrinck, 
Emmendingen, Germany 
Embedding paraffin Paraplast Plus® Sigma Aldrich,  
Steinheim, Germany 
Microscope slide Superfrost Plus® R. Langenbrinck, 
Emmendingen, Germany 
Microtome blade S35 Feather® A. Hartenstein GmbH, 
Würzburg, Germany 
 
Table 9. Devices and software 
Article Trade name/ Description Company 
Cooling plate Leica EG1150C- Modular 
Tissue Embedding Center 
 
Leica Microsystems, 
Nussloch, Germany 
Digital camera Leica DC300F- Digital 
camera systems for optimum 
image quality at low light 
intensity 
Leica Microsystems, 
Nussloch, Germany 
Drying chamber  Memmert GmbH & Co KG, 
Schwabach, Germany 
Microtome Leica RM2165-
fully motorized rotary 
microtome 
Leica Microsystems, 
Nussloch, Germany 
Paraffin elongation bath Leica HI 1210- Water bath 
for paraffin sections 
Leica Microsystems, 
Nussloch, Germany 
Paraffin embedding station Leica EG1140H-Modular 
tissue embedding station 
Leica Microsystems, 
Nussloch, Germany 
Stereomicroscope Leica DMLA Compound 
microscope 
Leica Microsystems, 
Nussloch, Germany 
Software Stepanizer stereology tool 
for manual stereological 
assessment of digital images 
www.stepanizer.com 
Software QWin V3- Processing and 
analysis software for 
quantitative microscopy 
Leica Microsystems, 
Nussloch, Germany 
Vacuum-tissue infiltration 
machine 
Leica TP 1050ß Tissue 
processor 
Leica Microsystems, 
Nussloch, Germany 
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3.1.5. Cardiomyocyte studies 
Table 10. Substances, devices and instruments  
Article  Trade Name/ Description Company 
Calcium chloride (CaCl2)  Merck KGaA 
Darmstadt, Germany 
Calcium chloride dehydrate 
(CaCl2 x 2 H2O) 
 Sigma-Aldrich, 
Seelze, Germany 
(±)-Carnitine hydrochloride  
 
 Sigma-Aldrich, 
Seelze, Germany 
Cell-edge detection system  SI Scientific Instruments 
GmbH, Munich, 
Germany 
Centrifuge Heraeus Megafuge 2.0R - 
Medium Bench Centrifuge 
Heraeus Instruments 
GmbH, Hanau, Germany  
Collagenase Collagenase Type II, CLS II 
 
Biochrom GmbH, 
Berlin, Germany 
Creatine monohydrate  Sigma-Aldrich, 
Seelze, Germany 
Cytosine- β-D-
arabinofuranoside 
 Sigma-Aldrich, 
Seelze, Germany 
Desiccator  Carl Roth GmbH & Co, 
Karlsruhe, Germany 
DL-isopropyl arterenol  Serva Electrophoresis 
GmbH, 
Heidelberg, Germany 
Falcon tube, 
15 ml, 50 ml 
 Greiner bio-One, 
Frickenhausen,Germany 
Fetal calf serum  PAA 
Laboratories GmbH, 
Cölbe, Germany 
Fura-2-AM Intracellular calcium 
indicator 
Thermo Scientific, 
N. Meridian Road, USA 
Glass pipette  Greiner bio-One, 
Frickenhausen,Germany 
Glucose monohydrate  Merck KGaA, 
Darmstadt, Germany 
HEPES (4-(2-
hydroxyethyl)-1-piperazine 
ethane sulfonic acid) 
 Sigma-Aldrich, 
St. Louis, USA 
Imaging system IonOptix imaging system IonOptix Corp., USA 
 
Isoprenaline  Serva Electrophoresis 
GmbH,  
Heidelberg, Germany 
Laminin  Roche Diagnostics 
GmbH, 
Mannheim, Germany 
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Line camera  SI Scientific Instruments 
GmbH,  
Munich, Germany 
Magnesium sulphate 
(MgSO4)  
 Merck KGaA,  
Darmstadt, Germany 
Magnesium sulfate 
heptahydrate  
(MgSO4 x 7 H2O)  
 Merck KGaA, 
Darmstadt, Germany 
Mechanical tissue chopper McIlwain™  Hugo Sachs Elektronik -
Harvard Apparatus 
GmbH, 
March, Germany 
Medium 199 (w/o sodium 
bicarbonate, w L-glutamine, 
w Earle´s salts) 
Medium M199 powder 
medium 
Biochrom GmbH, 
Berlin, Germany 
Microscope Olympus IX-71-Inverted 
fluorescence microscope 
Olympus,  
Hamburg, Germany 
MitoSOX Red mitochondrial 
superoxide indicator for 
live-cell imaging 
Invitrogen,  
Carlsbad, USA 
Monopotassium phosphate 
(KH2PO4) 
 Merck KGaA,  
Darmstadt, Germany 
Nylon mesh  NeoLab, 
Heidelberg, Germany 
Observation monitor  Philips GmbH, 
Herrsching, Germany 
Oscilloscope Goldstar OS-9020A Gold Star Co, 
Seoul, Korea 
Penicillin-Streptomycin 
(5,000 U/mL) 
 Gibco, Life Technologies 
GmbH,  
Darmstadt, Germany 
Phase contrast microscope  Nikon, 
Düsseldorf, Germany 
KCl 
 
 Merck KGaA, 
Darmstadt, Germany 
Scalpel Feather® Disposal Scalpel Pfm Medical AG, 
Cologne, Germany 
NaCl  Merck KGaA, 
Darmstadt, Germany 
Sodium pyruvate  Sigma-Aldrich, 
Seelze, Germany 
Tempol ) 4-Hydroxy-
TEMPO) 
 Sigma-Aldrich, 
Seelze, Germany 
Tweezer  Dumont tweezer (from 
Dumoxel, Nr. 7, bent, peak 
intensity 0.03 mm) 
Dumont, 
Montignez, Switzerland 
Taurine )2-
aminoethanesulfonic acid) 
 Sigma-Aldrich, 
Seelze, Germany 
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3.1.6. Immunoblotting 
Table 11. Substances, devices and instruments   
Article Trade name/ Description Company 
Absorbance reader Elx808 Absorbance 
microplate reader 
Bio Tek, 
Bad Friedrichshall, 
Germany 
Autoradiography film  Kodak BioMax Light Film, 
Rochester, USA 
Buffer protein sample preparation 
buffer )Laemmli buffer: 25 
mM Tris, 192 mM Glycin 
and 0.1% SDS) 
Self-made 
DC (detergent compatible) 
Protein Assay  
 Bio-Rad Laboratories, 
Munich, Germany 
ECL (enhanced 
chemiluminescence ) 
detection reagent 
Amersham ECL Western 
Blotting Detection Reagent 
 
GE Healthcare Life 
Sciences,  
Little Chalfont, UK 
Gel NuPAGE Bis-Tris Gel 
(10%(, protein precast gel 
Life Technologies, 
Darmstadt, Germany 
Homogenizer Precelly®24-Tissue 
homogenizer 
PeqLab,  
Erlangen, Germany 
phenylmethane sulfonyl 
fluoride (PMSF) 
 Sigma-Aldrich,  
St. Louis, USA 
Protease inhibitor cOmplete Roche Applied Science, 
Penzberg, Germany 
Protease inhibitor Sodium-Orthovanadate Sigma-Aldrich,  
St. Louis, USA 
Protein standard Precision Plus Protein™ 
Dual Color standards 
Bio-Rad Laboratories, 
Munich, Germany 
Scanner CanoScan 5000F Canon, Tokyo, Japan 
sodium dodecyl sulphate 
(SDS) 
 Bio-Rad Laboratories, 
Munich, Germanysds 
Software AlphaEaseFC software Alpha Innotec, 
San Leandro, USA 
Western blot membrane Nitrocellulose membrane Pall Corporation,  
Pensacola, USA 
Western blot membrane PVDF membrane ImmobilonTM-P, Millipore 
Corp, Bedford, USA 
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Table 12. Primary antibodies  
Antibody Cat. Nr. Company 
α-tubulin antibody (B-7) 
 
sc-5286 Santa Cruz Biotechnology, 
Santa Cruz, USA 
Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) 
CB1001 Calbiochem,  
Darmstadt, Germany 
Mitofusin-2 (N-terminal) M6319 Sigma Aldrich,  
Munich, Germany 
NCX (H-300) sc-32881 Santa Cruz Biotechnology, 
Santa Cruz, USA 
Phospholamban (FL-52) sc- 30142 Santa Cruz Biotechnology, 
Santa Cruz, USA 
p-phospholamban (phospho S16 + T17)  ab62170 Abcam, Cambridge, UK 
SERCA2 (C-20) sc-8094 Santa Cruz Biotechnology, 
Santa Cruz, USA 
UCP3 PA1-055 Thermo Fischer Scientific 
Inc, USA 
 
Table 13. Secondary antibodies  
Antibody Cat. Nr. Company 
Goat anti-mouse IgG (H+L) GAM-APHRP Affinity Biologicals Inc, 
Canada 
Peroxidase AffiniPure donkey anti-goat IgG 
(H+L) 
 
705-035-147  Jackson 
ImmunoResearch, USA 
Sheep anti-rabbit IgG (H+L) SAR-APHRP Affinity Biologicals Inc, 
Canada 
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3.1.7. Respiration measurements  
Table 14. Substances and devices  
Adenosine diphosphate 
(ADP) 
 Calbiochem,  
Darmstadt, Germany 
Antimycin A  
 
 Sigma-Aldrich,  
Seelze, Germany 
Adenosine 5′-triphosphate 
(ATP) disodium salt hydrate 
 Sigma-Aldrich,  
Seelze, Germany 
Bovine serum albumin 
(BSA) 
Essentially fatty acid free 
(fraction V) 
Sigma-Aldrich,  
Seelze, Germany 
Catalase 
 
Lyophilized powder, 2,000-
5,000 units/mg protein 
Sigma-Alrdrich, 
Seelze, Germany 
Dithiothreitol (DTT) Reducing agent Sigma-Alrdrich,  
Seelze, Germany 
DL-Octanoyl-carnitine-
hydrochloride  
 Tocris Bioscience, 
Bristol, UK 
Ethylene glycol-bis (β-
aminoethyl ether (EGTA) 
 
 
Sigma-Aldrich,  
Seelze, Germany 
Glutamate  Sigma-Aldrich,  
Seelze, Germany 
HEPES (4-(2-
hydroxyethyl)-1-piperazine 
ethanesulfonic acid) 
 Sigma-Aldrich,  
Seelze, Germany 
Imidazole  Fluka (Sigma-Alrdrich), 
Steinheim, Germany 
K-Lactobionate 
 
 Sigma-Alrdrich,  
Seelze, Germany 
L-Glutamic acid  
 
 Sigma-Aldrich,  
Seelze, Germany 
L-Malic acid   Sigma-Aldrich,  
Seelze, Germany 
Magnesium sulphate 
(MgSO4)  
 Merck KGaA,  
Darmstadt, Germany 
4-Morpholineethanesulfonic 
acid (MES) hydrate 
 Sigma-Alrdrich,  
Seelze, Germany 
Magnesium sulfate 
hexahydrate  
(MgCl2 x 6 H2O) 
 Sigma-Alrdrich, 
Seelze, Germany 
Monopotassium phosphate 
(KH2PO4) 
 Merck KGaA,  
Darmstadt, Germany 
Oxygraph-2K 
 
 Oroboros instruments, 
Innsbruck, Austria 
Phosphocreatine disodium 
salt hydrate 
 Sigma-Alrdrich,  
Seelze, Germany 
Pyruvic acid  
 
 Sigma-Aldrich  
Seelze, Germany 
Saponin  Sigma-Aldrich  
Seelze, Germany 
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Software DataLab software Oroboros Instruments, 
Innsbruck, Austria 
Succinate disodium salt, 
hexahydrate 
 Sigma-Aldrich  
Seelze, Germany 
Sucrose  Carl Roth GmbH & Co, 
Karlsruhe, Germany 
Taurine  Sigma-Alrdrich,  
Seelze, Germany 
 
3.1.8. RNA analysis 
Table 15. Substances, devices and instruments  
iScript cDNA Synthesis Kit  Bio-Rad, Berkeley, USA 
iTaq SYBR Green supermix 
with ROX 
 Bio-Rad, Hercules, USA 
NanoDrop  PeqLab, Erlangen, Germany 
Real-time PCR system Mx3000P QPCR Systems 
 
Agilent Technologies,  
Santa Clara, USA 
Rneasy Micro kit  Qiagen, Hilden, Germany 
SYBR Safe DNA Gel Stain  Invitrogen, Carlsbad, USA 
 
3.2. Methods 
3.2.1. PAB  
This model induces a pulmonary stenosis and is used as a model of pressure overload-induced 
RVH and right heart failure [162]. Thin fragile walls of the pulmonary trunk are as limiting 
factor for making this model [53]. Furthermore, inability of the RV to withstand stress during 
pulmonary artery manipulation should be considered as a limiting factor [53]. 
3.2.1.1. Anesthesia 
Prior to endotracheal intubation, the mice were placed inside a transparent chamber and a gas 
mixture of 3-4% isoflurane rest O2 was introduced into the chamber to initiate anesthesia. 
3.2.1.2. Endotracheal intubation 
Intubation set up was prepared as described here. An endotracheal tube was prepared from the 
plastic part of a shortened intravenous catheter (20G x 1¼"). A blunted needle was inserted to 
this endotracheal tube in order to make it hard enough for the intubation process. The needle 
part was used to facilitate the introduction of the tracheal tube into the direction of the larynx 
and the epiglottis region. A surgical stereomicroscope (Leica MS5) was used for intubation and 
surgery procedures. A power light with easily bending horns was provided to illuminate the 
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larynx and operation region during intubation and operation. For intubation, the anesthetized 
mouse should be hanged on the blunted needle part of the intravenous catheter (14G x 2"). This 
needle part was connected to a 50 ml syringe, both were fixed on a retort stand using a clamp. 
The anesthetized mouse was taken out of the anesthesia chamber and suspended on the 
intubation set up by its superior incisor teeth. The ventral area of neck was trans illuminated by 
light source to make the intubation procedure possible. A curved forceps was used to firmly 
hold the tongue and slightly move it upwards. The lower jaw was kept open by a straight forceps 
in a way that vocal cords and trachea could be visualized. Then, the tracheal tube was gently 
inserted into the trachea, passing the vocal cords. The needle part was removed out of the 
trachea while the plastic part was kept in place. 
Application of a small drop of lidocaine on tip of the tracheal tube helped to reduce the gag 
reflex. 
3.2.1.3. Ventilation 
After intubation, the mouse was supine located on a plate. A modified Y shape connector linked 
the tracheal tube to a ventilator. Continuous inhalation of 1.5-2.5% isoflurane supplemented 
with 100% O2 provided maintenance of anesthesia. The tidal volume was adjusted as 10 µl per 
gram of body weight (BW) and ventilation frequency to 150 strokes per minute. Positive end-
expiratory pressure equal to 1 cm of water column was adjusted in order to avoid the collapse 
of alveoli during mechanical expiration. 
3.2.1.4. Surgical procedure 
Half an hour before starting the operation, a dose of analgesic buprenorphine hydrochloride 
(Temgesic®, 0.1 mg/kg) was given subcutaneously. The mouse was positioned and fixed by 
strands of surgical tapes (Durapore®) on its right side with the chest rotated and exposed to the 
operating person. The surgical plate was located in a shallow double layer plastic box. In this 
plastic box, the temperature could be kept around 40°C by circulating warm water in order to 
maintain the body temperature of the mouse. To prevent dryness of the cornea, sterile 
ophthalmic ointment (Bepanthen®) was applied on the eyes. 
Before starting the surgery, onset of deep anesthesia was confirmed by loss of the pedal 
withdrawal reflex. A subcutaneous injection of 0.3 to 0.5 ml of NaCl solution was provided to 
compensate for the fluid loss during operation process. Chest area was completely shaved and 
disinfected with a mixture of 50% 2-propanol and 1% povidone-iodine solution 
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(Braunoderm®). The second intercostal space is the proper approach to obtain the target 
vessels. By using a surgical scalpel, a 1 cm long incision was made on the skin of the left 
thoracic region of the mouse. The chest muscles were kept back with a few self-made retractors 
prepared from dulled 20G needles. Intercostal muscles in the second intercostal space were 
incised and the incision was also kept open carefully with the help of self-made retractors. In 
order to visualize the main pulmonary trunk the pericardium was mobilized with the help of a 
forceps. Careful dissection of the pulmonary trunk from the ascending aorta and left atrium was 
carried out by a blunt forceps until making a tunnel under the pulmonary trunk. Afterwards, a 
small titanium hemoclip (Weck Hemoclip® Traditional) was positioned around the pulmonary 
artery to induce constriction with a width of 0.35 mm which corresponds to a stenosis of 65-
70% [163]. Subsequently, interrupted suturing technique with non-absorbable sterile surgical 
suture (6-0 Prolene) was used to close the chest area around adjacent ribs. The same thread and 
continuous suturing technique was used for closure of the skin incision. The wound was treated 
with a mixture of 50% 2-propanol and 1% povidone-iodine solution. After surgery, the mice 
received 100 µl of a 5% glucose solution subcutaneously. After recovery from anesthesia and 
gaining back all reflexes, the animal was extubated. The mice were then transferred to a 
standard rodent cage with free access to food and water in a room of a temperature of 25°C for 
a few hours until transfer to the animal facility. Depending on clinical findings, one dose or a 
few doses of buprenorphine hydrochloride (0.1 mg/kg) was given subcutaneously. 
Control mice were subjected to sham operation which includes all surgical steps except stenosis 
induction by means of the hemoclip. 
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Figure 3. Pulmonary artery banding in mice 
Careful dissection of the pulmonary trunk from the ascending aorta and left atrium provides 
enough space around the pulmonary trunk. Using a clip applier, a hemoclip will be positioned 
around the pulmonary artery to induce constriction with a width of 0.35 mm which corresponds 
to a stenosis of 65-70%. 
 
3.2.1.5. Animal groups  
Both UCP2 KO and C57BL/6J mice were divided into two groups receiving either PAB or 
sham operation. Experimental time period was 22 days together. In this model, only males 
were chosen for the experiment. 
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3.2.1.6. Experimental design 
 
Echocardiography (Echo) was performed one day before the pulmonary artery banding 
(PAB)/Sham operation (OP) as well as 7 and 20 days after the OP. In vivo hemodynamic 
measurements and sampling were done 21 days after OP. 
 
3.2.2. Echocardiography 
3.2.2.1. Echocardiographic procedure 
Echocardiography is a non-invasive and inexpensive imaging tool capable of repeatable 
evaluation of the cardiovascular system in laboratory animals. Echocardiography was 
performed using a commercially available Vevo® 2100 high-resolution imaging system 
equipped with a 40-MHz linear-array transducer. Echocardiography was performed one day 
before the operation as well as 7 and 20 days after the operation. To carry out the ultrasound 
examination, the animal was first placed in a transparent chamber for induction of anesthesia. 
3-4% isoflurane in 100% O2 at a flow rate of 2 L/min was used to initiate anesthesia. 
Afterwards, the animal was carefully placed in  supine position on a heating plate with all limbs 
taped to ECG electrodes for HR monitoring. Subsequently, the snout was placed within a nose 
cone connected to the anesthetic system to maintain a steady-state sedation level by applying 
1.0-1.5% isoflurane in 100% O2. A single channel ECG was recorded during echocardiographic 
examination. A lubricated rectal thermometer was gently inserted inside the rectum to monitor 
body temperature and keep it at 37°C. In order to protect the cornea from drying, an ophthalmic 
ointment dexpanthenol (Bepanthen®) was applied to the eyes. The chest as well as cranial 
abdominal area were shaved to improve the quality of the echocardiographic images. 
Afterwards, the chest area was covered with a layer of a bubble free preheated ultrasound gel. 
Measurement of RV free wall thickness (RVWT) was done in the modified parasternal long-
axis view. Right ventricular outflow tract (RVOT) dimension was measured from the RVOT 
view at the level of the aortic valve. For assessment of right ventricular performance, the RV 
myocardial performance index (MPI) and tricuspid annular plane systolic excursion (TAPSE) 
were measured. The apical four chamber view was used for evaluation of TPASE in a way that 
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the M-mode cursor was placed at the junction of the tricuspid valve plane and the RV free wall. 
Also in apical four chamber view, the MPI (also called Tei index) was measured by tissue 
doppler imaging (TDI) at the lateral part of the fibrous annulus of the tricuspid annulus. MPI 
was calculated as the sum of isovolumic contraction time (IVCT) and isovolumic relaxation 
time (IVRT) divided by the ejection time (ET). Aortic velocity time integral was evaluated from 
the suprasternal view. Pulse wave aortic doppler recordings as well as measurements of the 
proximal ascending aortic diameter were used for calculation of the aortic stroke volume 
(SVao).The aortic diameter as measured using M-mode echocardiography at the level of the 
proximal ascending aorta. The whole echocardiography procedure lasted 25-35 minutes. The 
echocardiographic parameters were calculated off-line using Vevo® LAB software. 
After echocardiography assessment the mouse was carefully cleaned from ultrasound gel and 
transferred to a standard rodent cage with free access to food and water. The mouse was 
observed until it completely regained consciousness as well as motor skills. Afterwards, the 
mouse was brought back to the animal facility. 
3.2.2.2. Echocardiographic parameters 
Right ventricular internal diameter (RVID) 
The RVID describes the inner diameter of the RV. It was appointed as the maximum distance 
of the free wall of the RV to the septum measured in the apical four-chamber view and in the 
unit of mm. With the help of RVID, one can determine the degree of dilation of the RV. 
Myocardial performance index (MPI) or Tei index 
The MPI/Tei index arises from the sum of IVCT and IVRT divided by ET. These values are 
measured by TDI. The MPI is thus a parameter which characterizes the global function (systolic 
and diastolic) of the RV. An increase in the MPI is equivalent to a deterioration of the global 
cardiac function: the ET decreases in proportion to the isovolumetric contraction and relaxation; 
therefore the window of time in which a blood transport is possible shortens. Even the Tei index 
is used as a prognostic factor in patients with PH [164, 165]. 
Cardiac output (CO) 
The CO is the volume of blood that is pumped from the heart through the ascending aorta into 
the bloodstream in one minute. It is calculated from stroke volume (SV) x HR and is expressed 
in milliliters per minute. The SV can be determined during the echocardiography of the left 
ventricular outflow tract (LVOT). It is calculated from the diameter of LVOT and the integral 
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of the flow rate within the aorta during the systole called velocity time integral (VTI). As a 
formula CO will be calculated: CO = (LVOT x VTI) x HR. A decrease in cardiac-volume means 
a deterioration of the pumping function of the heart. 
Tricuspid annular plane systolic excursion (TAPSE) 
TAPSE is the distance traveled by the tricuspid ring between end-diastole and end-systole and 
is measured in mm. It is a parameter for the longitudinal function of the RV and is correlated 
with right ventricular ejection fraction (SV/end-diastolic volume x 100). A decrease of the value 
of TAPSE shows reduced contraction movement and thus restricting the systolic function of 
the RV. This parameter is used as an important prognostic factor for the survival of patients 
with PH [164, 165]. 
3.2.3. Hemodynamic assessment 
3.2.3.1. Animal preparation 
In vivo hemodynamic measurements were done 21 days after PAB operation. Approximately 
15 minutes prior to measurement, the mouse was given heparin (1 IU/g) intraperitoneally. 
Afterwards, the pressure transducer and tubes of measurement system as well as the catheter 
were flushed with physiologic saline to be free of bubbles. The HSE-HA PULMODYN W 
software was started and the recording windows for RVSP and systemic arterial pressure (SAP) 
were opened. In our experimental work, combination of ketamine hydrochloride (Ketamin 
10%®, 40 μg/g) and xylazine (Xylazin 2%, 0.6 μg/g) was administered intraperitoneally. This 
mixture has the advantage of rapid onset of anesthesia with an adequate duration of anesthesia. 
After reaching deep anesthesia defined as loss of pedal removal reflex, the mouse was placed 
on its supine position on a rubber pad located within a flat double-walled plastic shell. 
Circulation of 40°C water around the plastic shell helped to maintain physiological body 
temperature. A mixture of 50% 2-propanol and 1% povidone-iodine solution was applied on 
the neck region for disinfection. Subsequently, a 1-2 cm midline incision from below the 
mandible to the thoracic inlet was made on the skin and the mandibular glands and muscle layer 
beneath were pulled aside in a fine way until the trachea was visible. With the help of a curved 
forceps, a piece of thread was advanced under the trachea and a loose knot was made around it. 
After making a tiny incision in the trachea, a self-made tracheal tube was inserted and was 
afterwards connected to the ventilator. To fix the tracheal tube inside the trachea, the knot was 
tightly stretched. The respiratory frequency and tidal volume were adjusted to 150 breaths per 
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minute and 10 µl per gram BW subsequently. A column of water provided 1 cm water positive-
end expiratory pressure in order to avoid collapse of the alveoli during mechanical inspiration. 
3.2.3.2. Preparation of vessels 
Fluid filled pressure transducer (APT300) made us capable of direct and continuous 
measurements of arterial pressure as well as ventricular systolic pressure. Pressures were 
recorded as analog signals through the fluid-filled pressure transducer. These analog signals 
were amplified and converted into digital signals with help of a transformer.  
The left carotid artery was exposed carefully by dissecting omohyoid muscle longitudinally by 
means of a fine, curved and blunt forceps. Also, adjacent vagus nerve was gently separated and 
pulled aside. Using a thread, two ligatures were made around the exposed vessel. The cranial 
suture was ligated and totally tied up, while clamped using a tape to cranial region of plastic 
shell. The caudal ligature was presented loosely. Subsequently, the arterial catheter was 
positioned next to the artery and calibration value for SAP was set by adjusting the pressure 
transducer to zero mmHg. At entrance of chest, carotid artery was clamped by means of a 
vascular clip. Thereafter, a small incision (arteriotomy) proximal to the clip was made; catheter 
was inserted 2-3 mm in the direction of heart and was secured in place by total ligation of loose 
ligature. The vascular clip was removed and the catheter was pushed into the ascending aorta 
for about 11-12 mm until SAP would be recorded [166, 167]. 
The right jugular vein was exposed after dissecting from surrounding connective tissue. A loose 
tie on both cranial and caudal ends of the vessel was placed. After the venous catheter was 
located next to the jugular vein, calibration value for RVSP was set by adjusting the pressure 
transducer to zero mmHg. This step was followed by making an incision on jugular vein large 
enough to pass the catheter, between the two ligatures and introducing the catheter. Afterwards, 
the catheter was pushed approximately 5 mm into the vein and meanwhile the caudal ligature 
was quickly stretched downwards in order to prevent bleeding. The RVSP corresponds to an 
intact pulmonary artery systolic pressure [168]. 
The duration of recording for both SAP and RVSP was 10-15 min. 
3.2.3.3. Plasma preparation 
After moistening thorax and abdomen area with mixture of 50% 2-propanol and 1% povidone-
iodine solution, an incision from umbilicus area towards manubrium sternum was made. 
Directly below the ribs, skin and muscle layers on both sides of the median line were cut to 
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open the abdominal cavity. Diaphragm was incised and rib cage was spread apart laterally; 
fixed with curved 24G needles. LV at apex was punctured by a 1ml self-made heparinized 
syringe and connected needle (24 G) to take blood. The blood was transferred to an eppendorf 
tube and centrifuged at 9,500 x g for 15 minutes. Plasma was pipetted into a screw cap tube, 
snap frozen in liquid nitrogen (-196°C) and stored at -80° C for further analysis. 
3.2.3.4. Tissue processing 
A piece of thread was directed under the pulmonary artery and aorta, making a loose ligature 
around them. This was followed by a small incision in RV, through which a cannula for flushing 
purpose was inserted into the pulmonary artery. The ligature was tightened and an opening was 
made in LV in order to drain rinsing solution. Afterwards, the lung was flushed from blood 
through the pulmonary artery with isotonic saline at a pressure of 22 cm water column. When 
the lung was empty of blood and looked white in appearance, right lung was removed, snap 
frozen in liquid nitrogen (-196°C) and stored at -80°C for later molecular biology analysis. 
Heart was removed out of thoracic cavity. Both atria and surrounding tissues were cut. The 
heart was divided into RV and LV plus intra-ventricular septum (S). The ratio of RV to BW 
and the ratio of RV to LV+S weight were calculated to determine the degree of RVH. Weight 
of both ventricles was measured by laboratory scale.  
Calculations are as below: 
RV (mg) divided by LV plus S (mg) 
RV (mg) divided by BW (g) 
Half of the hearts were planned to be used for molecular biology analysis. These hearts were 
stored in screw cap tubes and snap frozen in liquid nitrogen (-196°C). Remaining hearts were 
planned to be used for histological analysis. For this purpose, the separated ventricles were 
stored in histology cassette and kept for 24 hours in formalin. On second day, the fixed 
ventricles were transferred from formalin into 0.1 M phosphate buffered saline (PBS) and kept 
for another 24 hours at 4°C. On day 3, they were transferred into 50% ethanol, and on day 4 
into 70% ethanol until further use for the histological preparations. 
In a few mice, thoracic cavity was opened and mice were euthanized by intracardiac 
administration of KCl solution (made isotonic with NaCl). This solution induced cardiac arrest 
at diastolic phase by eliminating the potassium concentration gradient and decreasing the 
resting membrane [169, 170]. Diastolic arrest of cardiomyocytes fixed all cells in round shape. 
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The taken hearts were split horizontally and transferred to formalin. The next steps were done 
as described previously for lung and heart tissues. 
3.2.4. Histological Studies 
3.2.4.1. Embedding and slide preparation 
Draining step of ventricles already stored in 70% ethanol was done overnight in automated 
tissue processing machine through a routine program. Subsequently, tissues were embedded 
using embedding machine and cooled down on a cooling plate until the wax blocks containing 
tissues could be drove out of their molds. The histological section was made into 3 µm thick 
slices, mounted on slides and dried on a hotplate. Sections were incubated at 37°C in heating 
cabinet. 
3.2.4.2. Collagen content measurement 
3.2.4.2.1. Sirius Red staining of histology slides 
To prepare PicroSirius Red solution 0.2 g Sirius Red was dissolved in 200 ml of picric acid and 
the resulting solution was filtered through a filter paper to remove solid particles. After that, the 
pH was adjusted to 2.0. 
Sirius Red staining of slides was done according the following protocol: 
Table 16. Sirius Red staining protocol 
Dewaxing and rehydration of paraffin-embedded tissue sections 
60 Minutes Incubation at 58°C 
3 ×10 Minutes Xylol 
2 × 5 Minutes Ethanol absolute 99.6% 
5 Minutes Ethanol 96% 
5 Minutes Ethanol 70% 
Staining protocol 
60 Minutes 0.1% Picro SiriusRed solution (protected from light) 
3 × 2   Minutes 1% acetic acid (for washing) 
Rinse off Aqua dest. 
Dehydration of paraffin-embedded tissue sections 
1 Minute Aqua dest. 
2 × 2 Minutes Ethanol 96% 
2 × 5 Minutes Isopropyl alcohol 
3 × 5 Minutes Xylol 
Mounting with Pertex® 
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3.2.4.2.2. Analysis of interstitial and perivascular collagen content 
The percentage of collagen fibers in the right ventricles was measured using Leica QWin 
standard analysing software, developed by the Leica Macro Company. The longitudinal 
sections of the RV were stained with Sirius Red which binds to collagen fibers and gives a red 
color. The surrounding tissue containing no collagen, was shown in yellow. The sections were 
counted in meander-shaped movements with the help of 630-fold magnification. Every second 
image in every second row was analysed so that totally 40-90 pictures were taken depending 
on the size of the RV. The percentage of collagen content per unit area was transferred. Stained 
vessels were excluded from the measurement. The total collagen content of the RV was 
calculated as the average of all taken images. 
3.2.4.3. Ratio of capillaries to cardiomyocytes 
3.2.4.3.1. Wheat germ agglutinin (WGA) / Isolectin B4-immunostaining 
20-fold concentrated tris buffered saline (TBS) was prepared as below: 
-122 g Trizma base 
-180 g NaCl 
-Aqua dest. up to 1000 ml 
The solution was diluted 20 times as 1-fold buffer and the pH adjusted to 8.4. 
Preparation of slides for immunostaining was done according the following protocol: 
Table 17. Immunostaining protocol of wheat germ agglutinin / isolectin B4 
Dewaxing and rehydration of paraffin-embedded tissue sections as table 16 
2 × 5 Minutes TBS (for washing) 
30 Minutes Proteinase K digestion 
3 × 5 Minutes TBS (for washing) 
2 Minutes BSA 10% (for blocking) 
4 × 5 Minutes TBS (for washing) 
Overnight WGA-FITC (1:150) 
IB4-TRITC (1:150) in TBS 
DAPI (1:200) 
6 × 20  Minutes TBS (for washing) 
1 Minute Aqua dest. 
7 Minutes In heating incubator at 37°C (for drying) 
Mounting with Dako mounting medium 
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3.2.4.3.2. Analysis of the number of cardiomyocytes and capillaries 
For this purpose, horizontal 3µm-thick sections of RV with a distance of 20 µm were made and 
tagged with isolectin. This reaction is based on coupling of fluorescent dyes to most of proteins 
in plants through highly specific bonds to sugar residues which are called lectins. WGA was 
conjugated with the fluorescent dye fluorescein isothiocyanate (FITC) and would bind to N-
acetyl-D-glucosamine residues. At 488 nm excitation wavelength, the cell wall of cardiac 
myocytes depicted green color assigned to his dye. The isolectin B4 (IB4) from the African 
plant Griffonia simplicifolia was labelled with tetramethylrhodamine-5 (-6) isothiocyanate 
(TRITC) and coupled to α-galactosyl residues. It bound to endothelial cells and the capillaries 
appeared in red at an excitation wavelength of 594 nm. Nuclei were stained with 4 ', 6-
diamidino-2-phenylindole dihydrochloride (DAPI), which binds to DNA as intercalating agent. 
DAPI appears in blue under ultraviolet light. From each section 9-15 images were taken at 630 
× magnification and with the help of Leica QWin software. These pictures were then evaluated 
using the Stepanizer stereology tool, a software freely available on the internet 
(http://www.stepanizer.com). After counting the number of cardiomyocytes and capillaries, the 
ratio of whole capillaries to cardiomyocytes per ventricle were analysed. In another calculation, 
the number of capillaries per of cardiomyocytes were analysed. 
3.2.5. Isolation of ventricular cardiomyocytes 
The following solutions and buffers were used for preparation of cardiomyocytes: 
Calcium stock solution: 
CaCl2                           100 mM 
Perfusion medium (pH 7.4, carbogen gassed for rat cardiomyocytes): 
Glucose monohydrate 11  mM 
HEPES 25  mM 
KCl 2.6 mM 
KH2PO4 1.2 mM 
MgSO4 x 7 H2O 1.2 mM 
NaCl 110 mM 
 
Collagenase buffer: 
CaCl2 100 mM 12.5 µl 
Collagenase 25   mg 
Perfusion medium 5     ml 
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The following solutions were used for culturing isolated cardiomyocytes: 
CCT medium (sterile filtered, pH 7.4): 
Medium 199 2   packages 
Distilled water 10 L 
HEPES 36 g 
Creatine 5  mM 
DL-carnitine 5  mM 
Taurine 5  mM 
Cytosine- β-D-
arabinofuranoside 
10 mg 
 
Pre-incubation Medium: 
CCT medium (sterile filtrated, pH 7.4) x     ml 
FCS (rat cardiomyocytes)/ Laminin (mouse cardiomyocytes) 4% (v/v) / 10 µl/1 ml 
Penicillin/ Streptomycin 2% (v/v) 
 
CCT culture medium (for rat cardiomyocytes): 
CCT Medium 
(sterile filtrated, pH 7.4) 
 x    ml 
Penicillin/ Streptomycin 2% (v/v) 
 
Zappel buffer (sterile filtered, pH 7.4, for mouse cardiomyocytes): 
NaCl 118 mM 
KH2PO4 1.2  mM 
KCl 4.7  mM 
Glucose  5     mM 
MgSO4 0.8  mM 
HEPES 10   mM 
CaCl2 dihydrate 2.5  mM 
Sodium pyruvate 1.9  mM 
 
3.2.5.1. Isolation of rat ventricular cardiomyocytes 
Ventricular heart muscle cells were isolated by Langendorff perfusion system from 
approximately 200 gram adult male Wistar rats as described previously [171]. 
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3.2.5.1.1. Perfusion system preparation, heart preparation and perfusion 
The Langendorff perfusion system was rinsed with 200 ml distilled water. The water was 
replaced with 20 ml perfusion buffer and allowed to circulate for 5 minutes inside the system. 
The system was filled with 80 ml bubble-free perfusion buffer, gassed continuously with 
carbogen (5% CO2-95% O2) to obtain a constant pH value and let the system warm up to 37°C.  
Rats were put in a small desiccator and deeply anesthetized using 4-5% Isoflurane. After 
cervical dislocation, chest area was opened, heart and lung were excised and transferred to a 
petri dish filled with ice cold physiological saline solution. After removal of lung, oesophagus, 
trachea, thymus, and aorta excluding the aortic arch; the heart was mounted from the aortic part 
over the cannula provided in Langendorff perfusion apparatus, by help of two forceps. The 
aorta was fixed with crocodile clip. It is important to do these steps quickly. It was checked that 
the cannula was not inserted too deeply into the heart; otherwise perfusion via the coronary 
vessels would be no longer possible. Before fixing the heart with thread to perfusion system, 
the valve was opened in order to see if vessels are well perfused. After fixing the heart by 
making a ligature around cannula, perfusion was started in non-recirculating mode with 
perfusion buffer at flow rate of one drop per second for 5 minutes, this allowed blood to wash 
away. Approximately 35 ml perfusion buffer was used for this step. Then, the collagenase 
buffer was added to the top reservoir of the system while a collecting funnel wrapped with 
parafilm was located under the heart. Perfusion was continued in recirculating mode for 25 
minutes more. 
3.2.5.1.2. Heart enzymatic digestion and separation of cardiomyocytes from other cell 
types 
When the heart looks smooth, perfusion can be stopped which also depends on the activity and 
quality of collagenase enzyme. After separation of ventricle from atrium and aorta, ventricle 
was transferred to another petri dish in order to cut it into small pieces at slitting width of 0.7 
mm, using a tissue chopper. Chopping was continued using two scalpels on a watch glass. 
Chopped tissue was then transferred into a tube containing re-circulated buffer and gently 
triturated using a sterile 5 ml pipette twice per minute for 5 minutes at 37°C. The cell suspension 
was filtered through a nylon mesh (mesh size 200 µm) into a falcon and centrifuged at 400 rpm 
for 3 minutes. The pellet contained myocytes while the supernatant contained small non-
myocytes such as endothelial cells and fibroblasts. The pellet was resuspended in perfusate in 
which the final concentration of CaCl2 was increased stepwise to 200 µM and 400 µM. The 
resuspended pellet was centrifuged at 400 rpm for 2 minutes. Later on, the pellet was 
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resuspended in 12 ml of final concentration of 1 mM CaCl2 in perfusion buffer and spinned at 
300 rpm for 1 minute. After removing supernatant, the pellet was resuspended in CCT medium 
containing 2% penicillin/streptomycin and cells were transferred to culture dishes pre-coated 
overnight with 4% (v/v) fetal calf serum; modified accordingly [172]. 
3.2.5.1.3. Culture of cardiomyocytes 
After 1-2 hour(s) being kept in pre-incubation medium in 37°C under CO2 free condition, cells 
were ready to be washed once with CCT culture medium to remove damaged cells and leave a 
homogenous population of myocytes. This results in 90% living, intact, rod-shaped cells. 
Finally, cells were plated at a density of 4-7 × 104 elongated cells per 35 mm culture dish. In 
each culture a density of rod-shaped, living cells ranged from 40 to 60% was plated; modified 
accordingly [172]. 
3.2.5.2. Isolation of mouse ventricular cardiomyocytes 
Ventricular heart muscle cells were isolated from male C57BL/6J and UCP2-/- mice by 
Langendorff perfusion system as described previously [171, 173]. 
Perfusion system preparation, heart preparation and perfusion for mouse cardiomyocytes are 
similar to what already for rat ventricular isolation is explained. The perfusion buffer for mouse 
cardiomyocyte should not be carbogen gassed, while the rat cardiomyocytes were carbogen 
gassed. 
When the heart looks smooth enough, perfusion can be stopped. Ventricle was separated from 
atrium and aorta, chopped into small pieces at width of 0.7 mm with a tissue chopper and later 
on with scalpels. Chopped tissue was transferred into a tube containing circulated buffer and 
gently triturated with a 5 ml pipette twice per minute for 5 minutes at 37°C. After filtering 
through a nylon mesh, suspension was centrifuged at 400 rpm for 1 minute. Pellet was 
resuspended in perfusion medium including 100 mM CaCl2 (final concentration 125 µM) and 
centrifuged at 300 rpm for 1 minute. Perfusion medium containing 100 mM CaCl2 with final 
concentrations of 250 µM and 500 µM were used to resuspend the pellets every time after 
centrifugation was done at 300 rpm for 1 minute. After last centrifugation, pellet was 
resuspended in final concentration of 1 mM of CaCl2 in perfusion medium and the pellet which 
contains rod-shaped cardiomyocytes was plated on culture dishes pre-coated with laminin (1g/l) 
which allows pre-treatment of cells shortly (1 hour) before cell plating. Cells can be washed 
with CCT medium to remove round and non- attached cells at least 1 hour after being kept in 
37°C incubator without CO2, modified accordingly [172]. 
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3.2.6. Cell treatment 
Only cells showing rod-shape morphology and having no signs of sarcolemmal blebs were used 
for analysis. In this project, cells were studied either under basal condition or after application 
of 10 nM isoprenaline (ISO). ISO was used to stimulate β-adrenoceptors and all treated and un-
treated cells were incubated at 37°C, with 95% humidity after ISO was added to them. 
3.2.7. Electrical stimulation of cardiomyocytes 
A self-made plate cover with 2 rectangular electrodes was used for this purpose. 
It was made such that when the cover was placed on the plate, electrodes were situated into the 
cell culture medium. Electrodes were connected to the electrical stimulator which generated 
stimulation. Cells were stimulated via these two electrodes with biphasic electrical stimuli 
composed of two equal but opposite rectangular 50-V stimuli of 5 millisecond duration. 
Cardiomyocytes were exposed to 2 Hz stimulation. Contraction signals were recorded every 15 
seconds. The mean of these 4 measurements were used to define the mean shortening of each 
cell.  
The culture dishes containing cells in CCT culture medium (for rat myocytes) or Zappel buffer 
(for mouse myocytes) were mounted on the stage of an inverted microscope. As already 
explained, a special self-made cap with 2 rectangular AgCl electrodes was used for 
cardiomyocytes stimulation. Cell culture dishes were covered by this cap and cells were 
stimulated with biphasic electrical stimuli. Each cell was stimulated at 2 Hz for 1 minute. Every 
15 seconds, cell shortening, contraction velocity and relaxation velocity were measured using 
a line camera. The average of all four measurements per every minute and their mean provided 
us a frequency to define the contractility of the specific cell. Length of the cell was measured 
at a rate of 500 Hz via a line camera. Cells were allowed to contract at room temperature and 
analysed using a cell-edge detection system. Cells not responding to the given specific 
stimulation frequency were excluded from analysis. 
3.2.8. Determination of parameters of cell contraction 
Indexes of mechanical properties of isolated cardiomyocytes were assessed by cell-edge 
detection system which measures changes in myocyte length in response to electrical 
stimulation. The system consists of a phase contrast microscope, black and white linear camera 
and a software. This system enables cell visualizing, detection of its edges and calculation of 
the cell length differences between systole and diastole. 
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For observing cell contraction with line camera, the camera was moved to provide the image 
zone, where it was able to cover cell edges in horizontal position. At the end, it would provide 
a picture with the cell going to be screened. Additionally, the culture dish was moved so that 
the specific experimental cell was exactly in the proper place in the image zone. The line camera 
was turned until both cell ends were covered by the line camera. The image from the line camera 
was converted into electrical signals, presented on an oscillograph. The deflection time on the 
horizontal amplifier was adjusted to 0.1 millisecond per cm and the vertical amplifier was 
regulated at 5 millivolts per division (mV/div). Detectable brightness by line camera was 
represented on the oscillograph as varying y-deflections. Amplitudes representing cell borders 
could be identified by their horizontal movement. It was thus possible to observe the cell 
contraction on the oscillograph. 
The oscillograph operated as a bi-channel oscillograph while against the second channel a 
strong stress or tension of the interface rested. The oscillograph presented a horizontal line at a 
certain height on the screen, if it was readable. This line was shown at the height of zero when 
non-readable. The video camera was used for recording phase-contrast micrographs. The 
contractions of every single cell were determined from consecutive frozen video frames 
magnifying the cell’s picture up to 500-fold on a video monitor screen. The software program 
CELL provided a graph on the basis of cell length at different times, representing a curve of 
cell length dependent on time. Cell shortening was recognized by the software at the beginning 
of cell contraction. Cells were constantly paced, and four contractions were recorded every 15 
seconds. The average of these recordings was used as one data point.  
1: Load free cell shortening expressed as shortening amplitude normalized to diastolic cell 
lengths (dL/L%) 
2: The contraction velocity expressed as micrometres per second  
3: The relaxation velocity expressed as micrometres per second 
3.2.9. Calcium transient quantification 
3.2.9.1. Cell preparation 
In order to explain the potential effects of a calcium receptor stimulation on cell shortening, 
cytosolic Ca2+ concentration was measured with fluorescent indicator Fura-2-AM as already 
described [174]. Isolated cardiomyocytes were loaded with Fura-2-AM at 37°C. Cells attached 
to FCS-coated glass coverslips were incubated for 30 minutes in medium 199 with 
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acetoxymethyl ester of Fura-2 (2.5 µM). Later on, cells were washed twice with medium 199 
for 30 minutes to allow hydrolysis of the acetoxymethyl esters within the cell. The fluorescence 
signal from dye-loaded cells was 20-30 times higher than background fluorescence. 
3.2.9.2. Measurement of intracellular Ca2+ 
Cell loaded coverslips were introduced into a gas-tight, temperature-controlled (37°C) and 
transparent perfusion chamber while positioned in the light path of an Olympus IX71 inverted 
microscope. Fura-2-AM was excited with 340 and 380 nm wavelengths at 37°C. Emission of 
light at 500-520 nm wavelength from an area of 10 x10 µm within a single fluorescent cell was 
collected by an imaging system (ION Optix Corp, MA). The data were analysed as the ratio of 
light emitted at 340 nm to 380 nm wavelengths. Calcium transients of beating cells were 
determined while cells were submitted to field stimulation at 1 Hz. 
3.2.10. Superoxide release assessment by MitoSOX 
MitoSOX Red mitochondrial superoxide indicator was used to detect mitochondrial superoxide 
as described previously for PASMCs [175]. Cardiomyocytes seeded on coverslips were 
incubated at 37°C without CO2 in 5 µM MitoSOX diluted in Zappel buffer for 15 minutes. Once 
in the mitochondria, MitoSOX Red reagent was oxidized by superoxide and exhibited red 
fluorescence. MitoSOX was excited at 510 nm and fluorescence was measured at 580 nm. 
Emission waves were recorded at 510 nm. ISO (10 nM) was added after 2 minutes of steady 
state. 
3.2.11. Tempol studies with rat cardiomyocytes 
After cell isolation as described above, rat cardiomyocytes were cultured and incubated with 
tempol (4-hydroxy-2, 2, 6, 6-tetramethylpiperidin-1-oxyl) with final concentration of 1 mM per 
dish for 24 hours. The cells were washed with CCT medium and used for further investigations. 
3.2.12. Protein extraction  
Protein extracts were prepared from isolated cardiomyocytes as well as RV and LV tissues. 
3.2.12.1. Protein extraction from cardiomyocytes 
Isolated cardiomyocytes were scrapped off from culture dishes and treated with lysis buffer as 
already explained [176]. Protein concentration was measured and protein samples were used 
for western blot or stored at -20°C. 
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Lysis buffer (1ml, pH 6.7): 
DDT (500 nM) 100 µl 
Lysis buffer  
(self-made, 50 mM Tris/HCL) 
885 µl 
Phosphatase inhibitor 10  µl 
Protease inhibitor  5    µl 
 
After preparation, add 2% (w/v) sodium dodecyl sulphate (SDS) to it under the safety hood. 
3.2.12.2. Protein extraction from heart tissues 
RV and LV tissues were transferred into 2 ml screw cap tubes containing 150 µl ice cold lysis 
buffer and ceramic beads. The tissues were homogenized for 2 x 30 seconds in the Precellys®24 
homogenizer. The samples were then centrifuged for 5 minutes at 10,000 rpm, allowed to stay 
on ice for 15 minutes and the supernatant was then transferred into eppendorf tubes. Protein 
concentration was measured and protein samples were used for western blot or stored at -20°C. 
Lysis buffer: 
Ripa buffer 1000 µl 
cOmplete 40     µl 
PMSF (100 mM) 1       µl 
Sodium-Orthovanadate 
(200 mM) 
5       µl 
 
3.2.13. Protein concentration measurement 
The determination of protein concentration was performed using the DC protein assay, 
according to the principle of the Lowry assay which is a colorimetric assay. Prior to 
concentration measurement, samples were diluted 1:10 in Ripa buffer. As a reference, a 
standard series (from 0.2 mg/ml to 1.6 mg/ml) was prepared from bovine serum albumin (BSA). 
Pure Ripa buffer was used as blank. 5 µl of the blank, the standards and protein samples were 
pipetted into a 96-well microplate. This was followed by adding 25 µl of a reagent mixture (1 
ml of reagent A plus 20 µl reagent S) and 200 µl of reagent B to each well. Afterwards, the 
plate was placed in the absorbance reader Elx808 which measured the absorbance at 750 nm. 
The standard curve and protein concentration were calculated by means of software. 
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3.2.14. Western blot analysis 
3.2.14.1. Western blot with extracted cells 
20 µl of Laemmli buffer was added to 100 µl of each sample. After heating for 5 minutes at 
95°C, protein samples were loaded on NuPAGE Bis-Tris precast gels (Life Technologies) and 
transferred onto nitrocellulose membrane. Nonspecific proteins were blocked with 2% (w/v) 
BSA and membranes were subsequently incubated at room temperature for 2 hours with 
primary antibodies including anti-SERCA2(C-20) (1:200), anti-phospholamban (FL-52) 
(1:200), anti-p-phospholamban (phospho S16 + T17) (1:1000), anti-NCX (H-300) (1:200), anti-
Mitofusin-2 (N-terminal) (1:200) detecting calcium handling proteins and anti–GAPDH 
(1:4000) as loading control. After washing thrice with TBS-T buffer (Tris Buffered Saline + 
0.1% Tween-20), the membranes were re-incubated with secondary, horseradish peroxidise 
(HRP) conjugated antibodies including donkey anti-goat (1:2000), goat anti-mouse (1:2000), 
and sheep anti-rabbit (1:2000) for 1 hour at room temperature. After washing thrice, detection 
of bands’ density was done by enhanced chemiluminescence (ECL). 
3.2.14.2. Western blot with extracted tissues 
Anti-UCP3 (1:1000) and anti-α-tubulin (loading control, 1:5000) antibodies were used to detect 
the specific proteins in tissue homogenates. Extracted protein from RV and LV was separated 
on a 12% SDS polyacrylamide gel and subsequently after separation were transferred onto a 
0.45 µm polyvinylidene fluoride (PVDF) membrane using semidry transferring equipment. The 
unspecific sites were blocked with 6% non-fat dry milk in TBS-T buffer for 1 hour and the 
membranes were incubated overnight at 4°C with respective antibodies in 6% non-fat dry milk. 
Every incubation was preceded by five washes with TBS-T buffer for 10 minutes. The anti-
rabbit and anti-mouse IgG secondary antibody coupled to HRP were used in dilution of 1:5000 
for 1 hour at room temperature. Every incubation step was preceded by three washes with TBS-
T buffer for 10 minutes. Visualisation of immunoreactive sites was carried out by ECL. 
Membranes were exposed to autoradiography film. Scanning of the films was done by a 
scanner. AlphaEaseFC software was applied for analysis of the bands as well as densitometry. 
3.2.15. Determination of mitochondrial respiration in permeabilized muscle fibers 
3.2.15.1. Heart preparation 
After opening chest cavity heart was excised, aorta and pulmonary artery were removed, and 
later RV and LV were separated. Heart was cut lengthwise into small pieces and transferred 
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into a petri dish containing ice cold medium called BIOPS. BIOPS is a relaxing and biopsy 
preservation solution which biopsies can be kept in it for several hours at 0°C. Using a pair of 
sharp forceps all connecting tissues were removed while the petridish containing biopsies was 
kept still on ice. A period of approximately five minutes was enough in order to prepare samples 
by partially teasing apart and stretching them out, while tissues still remained connected in a 
mesh-like framework. A change from red to pale colour was observed in the separated fibers 
bundles, which would be a marker for evaluating the degree of separation. 
BIOPS medium (pH 7.1): 
ATP 5.77  mM 
Ca-EGTA buffer 10     mM 
DTT 0.5    mM 
Free calcium 0.1    µM 
Imidazole 20     mM 
K-MES 50     mM 
MgCl2 x 6 H2O 6.56  mM 
phosphocreatine 15     mM 
Taurine 20     mM 
 
3.2.15.2. Tissue permeabilization 
The whole process as already explained causes partial permeabilization of heart fiber bundles, 
but full permeabilization is possible through incubation in BIOPS medium containing saponin. 
The fiber bundles were quickly transferred into petri dish containing 2 ml of ice cold BIOPS 
including 20 µl saponin stock solution (5 mg/ml, final concentration 50 µg/ml). The petridish 
was put on a shaker in cold room (on ice) for 30 minutes, letting gentle agitation. Samples were 
quickly transferred from permeabilization solution into 2 ml of Mir06 which is a mitochondrial 
respiration medium. Shaking was continued by gentle agitation in cold room (on ice) for 10 
minutes more. 
Mir06 solution (pH 7.1): 
BSA 1     g/l 
Catalase 280 u/ml 
EGTA 0.5  mM 
HEPES 20   mM 
KH2PO4 10   mM 
K-lactobionate 60   mM 
MgCl2 x 6 H2O 3     mM 
Sucrose 110 mM 
Taurine 20   mM 
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3.2.15.3. Wet weight of sample 
Before using the samples for measurement in Oxygraph-2K chamber, several loosely connected 
fiber bundles were taken with a sharp pair of forceps (having angular tip), were placed for a 
few seconds on a filter paper and meanwhile the liquid from the tip of forceps was wiped with 
another filter paper. Afterwards, the samples were put immediately onto a small plastic surface 
on the table of a scale which was already tared. The wet weight was measured and the samples 
were immediately transferred into a petri dish containing ice cold Mir06.  
3.2.15.4. Respiration measurement with Oxygraph-2K 
The oxygen sensors were calibrated in Mir06 medium at 37°C while stoppers were partially 
inserted in order to avoid raw signals reaching the limiting value of 10V at high experimental 
oxygen concentrations. Respiration should be measured at 37°C in Mir06 medium which 
provides optimal protection of mitochondrial function. The samples were transferred into 
Oxygraph-2k chamber and immersed with a straight forceps into the medium stirring inside the 
chamber. The chamber was closed for the oxygen concentration signal to be stable. After that, 
a standard substrate- inhibitor protocol using pyruvate (5 mM), ADP (1 mM), glutamate (10 
mM) and malate (4 mM), octanoylcarnitine (0.25 mM), succinate (10 mM) and antimycin A (5 
µM) was applied for measurement of respiration in Mir06 medium. Oxygen consumption was 
calculated from the recorded data as the time derivative of the oxygen content in the chamber 
corrected to antimycin A, using DatLab software (Oroboros Instruments, Innsbruck, Austria). 
3.2.16. RNA extraction, cDNA synthesis and Real-Time PCR  
The isolation of ribonucleic acid (RNA) from tissue homogenates of the RV and LV was 
performed using the RNeasy Micro Kit (Qiagen). Following the RNA isolation, the 
concentration of RNA was determined spectrophotometrically by NanoDrop. The 
concentration measurement was accompanied by measurement of purity of extracted RNA. The 
preparation of complementary DNA (cDNA) was carried out by reverse transcription using the 
iScript cDNA Synthesis Kit (Bio-Rad). In each case 500 ng RNA was measured according to 
protocol "1 × (25°C, 5 min), 1 × (42°C, 30 min) followed by 1 × (85°C, 5 min)" reverse 
transcription. Afterwards, the total cDNA obtained from the RV and LV tissues was used to 
carry out real-time polymerase chain reaction (PCR) using a master mix for reverse 
transcription (RT) PCR (iTaq SYBR Green supermix with ROX, Bio-Rad) and Mx3000P 
QPCR System (Agilent Technologies). Hypoxanthine phosphoribosyltransferase (HPRT) was 
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used as housekeeping gene. Oligonucleotide sequence of mouse UCP3 and HPRT primers were 
designed as: 
Species Primer Orientation Sequence Accessing number 
Mouse UCP3 Sense TGCTGAAGATGGTGGCTCA NM_009464 
Antisense CCCGCAGTACCTGGACTTTC 
Mouse HPRT Sense GCTGACCTGCTGGATTAC NM_013556 
Antisense TTGGGGCTGTACTGCTTA 
Abbreviations: UCP3: Uncoupling protein 3; HPRT: Hypoxanthine phosphoribosyltransferase 
 
Used reaction condition was 1× (95°C, 10 min) followed by 45 × (95°C, 5 s; 60°C, 5 s, 72°C, 
10 s) and the extension phase was done at 72°C. Measurement of each gene was carried out as 
duplicate. Confirmation of the desired products formation was done by dissociation curves. 
Running the products on an agarose gel with SYBR Safe DNA Gel Stain (Invitrogen) was the 
next step. The calculation of ΔCt values was done by subtracting the Ct values of the target 
gene from the endogenous control [ΔCt = Ct (endogenous control) – Ct (target)]. 
Results 
 
80 
  
4. Results 
Data are presented as individual value plots or summary data plots. All data are expressed as 
mean ± standard error of mean (SEM). The different experimental groups were statistically 
analysed by either Student’s t-test or two-way ANOVA and Bonferroni post-hoc test in case of 
multiple comparisons. Values of p < 0.05 were considered as statistically significant.  
4.1. Effect of PAB on the right heart of UCP2-/- mice 
4.1.1. Increased RVSP in C57BL/6J (WT) and UCP2-/- mice subjected to PAB 
Hemodynamic measurements showed that PAB caused an increase in RVSP of comparable 
degree in WT and UCP2-/- mice, while it had no effect on SAP three weeks after operation. 
 
Figure 4. Hemodynamic measurements three weeks after PAB operation 
a) Right ventricular systolic pressure (RVSP) in C57BL/6J and UCP2 -/- mice (n = 5-13 each 
group) and b) systemic arterial pressure (SAP) in C57BL/6J and UCP2 -/- mice (n =5-14 each 
group) in a model of right ventricular hypertrophy (RVH) induced by pulmonary artery banding 
(PAB) three weeks after surgery. Control mice were subjected to sham surgery. Values are 
depicted as mean ± SEM; ****P < 0.0001 compared to corresponding sham mice; analysis by 
two way ANOVA. 
 
 
 
 
 
 
Results 
 
81 
  
4.1.2. Right heart hypertrophy in C57BL/6J (WT) and UCP2-/- mice subjected to PAB 
The ratio of the RV mass to BW and the ratio of RV mass to LV plus S mass was increased in 
both WT and UCP2 -/- mice to a similar degree after PAB. These data demonstrated induction 
of right heart hypertrophy in WT and UCP2-/- mice after PAB operation.  
 
Figure 5. Right heart hypertrophy three weeks after PAB 
a) Ratio of right ventricular mass to body weight (RV/BW) and b) ratio of right ventricular 
mass to left ventricular plus septal mass (RV/LV+S) as measures for right heart hypertrophy in 
C57BL/6J and UCP2-/- mice (n = 5-12 each group) three weeks after PAB operation. Control 
mice were subjected to sham operation. Values are depicted as mean ± SEM; **P < 0.01 and 
****P < 0.0001 compared to corresponding sham mice; interaction between genotype and 
treatment was statistically significant for RV/BW; analysis by two way ANOVA. 
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4.1.3. Preserved RV function in UCP2-/- mice and deteriorated RV function in C57BL/6J 
(WT) mice after PAB 
CO and TAPSE, representing global and right ventricular systolic function, respectively, were 
lower in UCP2-/- mice which received sham operation compared to sham-operated WT mice 
(Figures 6a,b). These parameters both decreased in WT mice after PAB compared to 
corresponding sham mice while they were preserved in UCP2-/- mice (Figures 6a,b). Global 
right heart function, determined as myocardial performance index (MPI or Tei index) was 
reduced in sham-operated UCP2-/- mice compared to WT mice subjected to sham operation 
(Figure 6c). After PAB, this parameter was deteriorated in WT mice whereas it remained 
preserved in UCP2-/- mice (Figure 6c). In sham-operated mice, RVWT was slightly higher in 
UCP2-/- mice compared to WT mice (Figures 6d, 7). The sham-operated UCP2-/- mice showed 
no difference in RVID in comparison to WT mice subjected to sham operation (Figures 6e, 7). 
PAB resulted in right ventricular dilatation as evidenced by an increase in RVID. However, in 
UCP2-/- mice, RVID was increased to a significantly lesser extent compared to WT mice. In 
summary, the echocardiographic data showed preserved right ventricular function in UCP2-/- 
mice after PAB operation in contrast to WT mice. 
* Echocardiography was performed by Dr. Baktybek Kojonazarov and Dr. Akylbek Sydykov, ECCPS, 
Justus-Liebig-University, Giessen  
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Figure 6. Echocardiographic findings three weeks after PAB 
a) Cardiac output (CO), b) tricuspid annular plane systolic excursion (TAPSE), c) myocardial 
performance index (MPI), d) right ventricular wall thickness (RVWT), e) right ventricular 
internal diameter (RVID) in C57BL/6J and UCP2-/- mice (n = 4-16 each group) three weeks 
after PAB or sham operation. Values are depicted as mean ± SEM; *p < 0.05, **p < 0.01, ***p 
< 0.001 and ****P < 0.0001; interaction between genotype and treatment was statistically 
significant for CO, TAPSE, MPI, RVWT and RVID; analysis by two way ANOVA.  
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Figure 7. Representative echocardiographic images three weeks after PAB 
Echocardiographic images demonstrating  right ventricular wall thickness (RVWT) and right 
ventricular internal diameter (RVID) in the right parasternal long axis view in a) C57BL/6J 
sham, b) C57BL/6J PAB, c) UCP2 -/- sham and d) UCP2 -/- PAB mice three weeks after PAB or 
sham operation. 
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4.1.4. Increased RV collagen content in C57BL/6J (WT) and UCP2-/- mice after PAB  
In order to find out the degree of fibrosis in the RV, the relation of the area of collagen fibers 
to the total area of the RV section was determined. Both WT and UCP2-/- mice showed 
increased myocardial fibrosis in the RV after PAB as evidenced by an increase in the RV 
content of collagen fibers (Figures 8a,b). Interestingly, the collagen content in PAB-operated 
UCP2-/- mice was significantly higher than in PAB-operated WT mice.  
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Figure 8. Percent of collagen content in the RV three weeks after PAB 
a) Percent of collagen content (n = 5-7 each group) and b) histologic sections of the right 
ventricle after staining with PicroSirius Red showing the right ventricular fibrosis in C57BL/6J 
and UCP2-/- three weeks after PAB or sham operation. The surrounding non-collagen-
containing tissue is shown in yellow. Values are depicted as mean ± SEM; **p < 0.01 and 
****P < 0.0001; interaction between genotype and treatment was statistically significant for 
collagen content; analysis by two way ANOVA. 
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4.1.5. Preserved degree of capillarization in C57BL/6J (WT) and UCP2-/- mice subjected 
to PAB 
The ratio of the number of capillaries to cardiomyocytes (Cap/Card) provides information on 
the oxygen supply of the heart muscle. Although the WT and UCP2-/- mice showed no 
difference in Cap/Card ratio after PAB (Figures 9a,c), the ratio of capillaries to CSA of 
cardiomyocyte was decreased in both groups of mice (Figure 9b). However, there was no 
difference between WT and UCP2-/- mice. 
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Figure 9. Ratio of capillaries to cardiomyocytes in the RV three weeks after PAB  
a) The ratio of capillaries to cardiomyocytes (Cap/Card), b) number of capillaries per cross 
sectional area (CSA) of cardiomyocytes in right ventricular sections (n = 5 each group), and c) 
representative picture showing right ventricular capillarization in C57BL/6J and UCP2-/- mice 
three weeks after PAB or sham operation. Values are depicted as mean ± SEM; *p < 0.05; 
analysis by two way ANOVA. 
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4.2. Effects of PAB on isolated cardiomyocytes 
4.2.1. Functional studies in isolated cardiomyocytes 
4.2.1.1. Improved fractional shortening of cardiomyocytes isolated from the RV of  
UCP2-/- mice after PAB compared to C57BL/6J (WT) mice 
Cardiomyocytes isolated from the RV of both WT and UCP2-/- mice showed an enhanced ratio 
of cell length shortening to diastolic cell length expressed as percent (dL/L%) under non-
stimulated conditions three weeks after PAB operation compared to sham mice (Figures 10a,c). 
However, in non-stimulated cardiomyocytes isolated from the RV of UCP2-/- mice subjected to 
PAB operation, factional cell shortening showed a higher value compared to cardiomyocytes 
from WT mice after PAB operation (Figures 10a,c). Stimulation with ISO led to a significant 
increase in fractional cell shortening of cardiomyocytes isolated from the RV of UCP2-/- mice 
after PAB operation, but not of cardiomyocytes from WT mice subjected to PAB operation 
(Figures 10b,c). Stimulated cardiomyocytes from the RV of WT mice showed no significant 
difference in fractional shortening to those from UCP2-/- mice after sham or PAB operation 
(Figures 10b,c). Interestingly, we found increased cell shortening in the cardiomyocytes 
isolated from the LV of sham- and PAB-operated UCP2-/- mice compared to WT mice under 
non-stimulated conditions (Figures 11a,c). However, after stimulation with ISO, cell shortening 
was increased in the cardiac myocytes from the LV of PAB-operated mice, but did not differ 
between genotypes (Figures 11b,c). 
* Cell shortening measurement was performed by AG Schlüter, Physiology Institute, Justus-Liebig-
University, Giessen 
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Figure 10. Fractional shortening of cardiomyocytes isolated from the RV three weeks 
after PAB 
Ratio of cell length shortening to diastolic cell length (dL/L) as percent (%) in cardiomyocytes 
isolated from the right ventricle (RV) a) under basal condition (n = 29-35 cells each group, from 
at least 3 isolations), and b) after stimulation with 10 nmol/L isoprenaline (ISO) (n = 36 cells 
each group, from at least 3 isolations). c) Single-cell recordings of cell shortening at 2 Hz 
stimulation. Values are depicted as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001; analysis by two way ANOVA. 
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Figure 11. Fractional shortening of cardiomyocytes isolated from the LV three weeks after 
PAB 
Ratio of cell length shortening to diastolic cell length (dL/L) as percent (%) in cardiomyocytes 
isolated from the left ventricle (LV) a) under basal condition (n = 52 cells each group, from at 
least 3 isolations), and b) after stimulation with 10 nmol/L isoprenaline (ISO) (n = 52 cells each 
group, from at least 3 isolations). c) Single-cell recordings of cell shortening at 2 Hz stimulation. 
Values are depicted as mean ± SEM; *p< 0.05 and **p < 0.01; analysis by two way ANOVA. 
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4.2.1.2. Improved contraction velocity of cardiomyocytes isolated from the RV of UCP2-/- 
mice after PAB compared to C57BL/6J (WT) mice 
Under non-stimulated conditions, the RV cardiomyocyte contraction velocity was increased 
after PAB compared to sham in both strains (Figure 12a), albeit to a higher degree in RV 
cardiomyocytes from UCP2-/- mice after stimulation with ISO (Figure 12b). PAB had no 
significant effect on the contraction velocity of unstimulated LV cardiomyocyte (Figure 12c). 
Stimulation with ISO resulted in a higher increase of the contraction velocity of UCP2-/- sham 
cardiomyocytes compared to sham WT cardiomyocytes isolated from LV (Figure 12d). In 
contrast, the ISO-stimulated contraction velocity was significantly increased in cardiomyocytes 
from PAB-operated WT mice and not in those from PAB-operated UCP2-/- mice (Figure 12d). 
* Contraction velocity measurement was performed by AG Schlüter, Physiology Institute, Justus-
Liebig-University, Giessen 
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Figure 12. Contraction velocity of cardiomyocytes isolated from the RV and LV three 
weeks after PAB 
Contraction velocity in a) cardiomyocytes isolated from the right ventricle (RV) under basal 
conditions (n = 30-36 cells each group, from at least 3 isolations), b) cardiomyocytes isolated 
from the RV after stimulation with 10 nmol/L isoprenaline (ISO) (n = 36 cells each group, from 
at least 3 isolations), c) cardiomyocyte isolated from the left ventricle (LV) under basal 
condition (n = 52 cells each group, from at least 3 isolations), and d) cardiomyocytes isolated 
from the LV after stimulation with 10 nmol/L ISO (n = 52 cells each group, from at least 3 
isolations). Values are depicted as mean ± SEM; *p < 0.05, **p < 0.01 and ***p < 0.001; 
interaction between genotype and treatment was statistically significant for LV Contraction 
Velocity after stimulation with ISO; analysis by two way ANOVA. 
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4.2.1.3. Improved relaxation velocity of cardiomyocytes isolated from the RV of UCP2-/- 
mice after PAB compared to C57BL/6J (WT) mice 
Under non-stimulated conditions, RV cardiomyocyte relaxation velocity was increased after 
PAB compared to sham in both strains (Figure 13a), albeit to a higher degree in RV 
cardiomyocytes from UCP2-/- mice after stimulation with ISO (Figure 13b). The relaxation 
velocity of non-stimulated LV cardiomyocytes showed no significant effect of PAB (Figure 
13c), In contrast, the ISO-stimulated relaxation velocity was significantly increased in 
cardiomyocytes from sham-operated UCP2-/- mice compared to those from sham-operated WT 
mice (Figure 13d). 
* Relaxation velocity measurement was performed by AG Schlüter, Physiology Institute, Justus-Liebig-
University, Giessen 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
95 
  
 
Figure 13. Relaxation velocity of cardiomyocytes isolated from the RV and LV three 
weeks after PAB 
Relaxation velocity in a) cardiomyocyte isolated from the right ventricle (RV) under basal 
conditions (n = 30-36 cells each group, from at least 3 isolations), b) cardiomyocytes isolated 
from the RV after stimulation with 10 nmol/L isoprenaline (ISO) (n = 36 cells each group, from 
at least 3 isolations), c) cardiomyocyte isolated from the left ventricle (LV) under basal 
condition (n = 52 cells each group, from at least 3 isolations), and d) cardiomyocytes isolated 
from the LV after stimulation with 10 nmol/L ISO (n = 52 cells each group, from at least 3 
isolations). Values are depicted as mean ± SEM; *p < 0.05, **p < 0.01 and ***p < 0.001; 
interaction between genotype and treatment was statistically significant for LV Relaxation 
Velocity after stimulation with ISO; analysis by two way ANOVA. 
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4.2.2. Calcium dynamics in isolated cardiomyocytes 
4.2.2.1. Increased calcium transients in cardiomyocytes from UCP2-/- mice after PAB 
compared to C57BL/6J (WT) mice  
To further investigate, if changes in contraction and relaxation were related to alterations in 
cellular calcium handling in these mice, we measured calcium transients in isolated 
cardiomyocytes. [Ca2+]i transients measured by Fura-2-AM were increased in cardiomyocytes 
isolated from the RV of PAB-operated UCP2-/- mice compared to those from PAB-operated 
WT mice (Figures 14a,c). No significant differences between UCP2-/- and WT mice subjected 
to PAB operation were noted in calcium transients of isolated cardiomyocytes from the LV 
(Figures14b,c). 
* Calcium transient measurement was performed by AG Schlüter, Physiology Institute, Justus-Liebig-
University, Giessen 
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Figure 14. Calcium transients in cardiomyocytes isolated from the RV and LV three weeks 
after PAB 
Quantitative analysis of Fura-2-AM fluorescence intensity (expressed in arbitrary units (a.u.)) 
indicating intracellular calcium ([Ca2+]i) transients in cardiomyocytes isolated from a) the right 
ventricle (RV) (n = 11-25 cells each group, from at least 3 isolations), and b) the left ventricle 
(LV) (n = 13-16 cells each group, from at least 3 isolations). Representative Ca2+ concentration 
traces during 5 seconds in individual cardiomyocytes isolated from c) the RV, and d) the LV. 
Values are depicted as mean ± SEM; **p < 0.01; analysis by two way ANOVA.  
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4.2.2.2. Decreased time of calcium to reach 50% of the basal value in cardiomyocytes from 
UCP2-/- mice after PAB compared to C57BL/6J (WT) mice 
The time of calcium to reach again 50% of its basal value after maximal calcium increase was 
measured in order to understand the relationship between cardiomyocyte relaxation and calcium 
handling. Cardiomyocytes isolated from the RV of UCP2-/- mice reached faster 50% of their 
basal calcium level, compared to WT cardiomyocytes after PAB operation, but also after sham 
operation (Figure 15a). In cardiomyocytes isolated from the LV of PAB-operated UCP2-/- and 
PAB-operated WT mice, no significant change was observed in the time of calcium to reach 
50% of its basal value (Figure 15b). 
* Measurement of Ca2+ Time-to-Basal 50% was performed by AG Schlüter, Physiology Institute, 
Justus-Liebig-University, Giessen 
 
 
Figure 15. The time of calcium to reach 50% of basal level in cardiomyocytes isolated 
from the RV and LV three weeks after PAB 
The time for the intracellular calcium ([Ca2+]i) to reach 50% of its basal level (Ca
2+ Time-to-
Basal 50%) in a) cardiomyocytes isolated from the right ventricle (RV), and b) cardiomyocytes 
isolated from the left ventricle (LV) (n = 11-25 cells each group, from at least 3 isolations). 
Values are depicted as mean ± SEM; *p < 0.05; analysis by two way ANOVA. 
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4.2.3. Expression of calcium handling proteins in cardiomyocytes from UCP2-/- mice after 
PAB compared to C57BL/6J (WT) mice 
To determine the source of intracellular calcium ([Ca2+]i) alterations, we examined the 
expression of regulatory proteins of cardiac calcium handling: The sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2a (SERCA2a), phospholamban (PLB), phosphorylated 
phospholamban (pPLB) and the Na+-Ca2+ exchanger (NCX) which are major determinants of 
diastolic calcium clearance.  
We also examined the expression of Mitofusin-2 (MFN2), a mitochondrial protein involved in 
SR-mitochondrial tethering, thereby regulating SR calcium handling. 
* Measurement of calcium handling proteins’ expression was performed by AG Schlüter, Physiology 
Institute, Justus-Liebig-University, Giessen 
4.2.3.1. Increased SERCA2a expression in RV cardiomyocytes from UCP2-/- mice after 
PAB compared to C57BL/6J (WT) mice 
Western blot analysis of protein extracts from cardiomyocytes isolated from the RV 
demonstrated an increase in the protein level of SERCA2a in cardiomyocytes from UCP2-/- 
mice subjected to PAB operation compared to the corresponding cardiomyocytes from sham-
operated UCP2-/- and PAB-operated WT mice (Figures 16a,c). No significant difference was 
observed between PAB-operated UCP2-/- and PAB-operated WT mice in the protein level of 
SERCA2a from LV cardiomyocytes (Figures 16b,d). 
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Figure 16. Expression of SERCA2a in cardiomyocytes isolated from the RV and LV three 
weeks after PAB 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a) protein expression level 
in cardiomyocytes determined by western blot in a) the right ventricle (RV), and b) the left 
ventricle (LV) (n = 4 each group). Data are given in percent (%) of the average value of the RV 
or LV of WT sham-operated mice. Densitometric analysis for SERCA2a expression was 
performed and values were normalized to glycerinaldehyd-3 phosphate-dehydrogenase 
(GAPDH) expression. Representative western blot of c) the RV, and d) the LV. Values are 
depicted as mean ± SEM; ***p < 0.001 and ****p < 0.0001; interaction between genotype and 
treatment was statistically significant for RV SERCA2a protein expression; analysis by two 
way ANOVA. 
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4.2.3.2. Unchanged NCX expression in cardiomyocytes from UCP2-/- mice after PAB 
compared to C57BL/6J (WT) mice  
Western blot analysis of protein extracts from cardiomyocytes isolated from the RV and LV 
demonstrated no change in the protein level of NCX between UCP2-/- and WT mice subjected 
to PAB operation compared to the corresponding sham-operated mice (Figures 17a-d). 
 
 
Figure 17. Expression of NCX in cardiomyocytes isolated from the RV and LV three 
weeks after PAB 
Na+-Ca2+ exchanger (NCX) protein expression level in cardiomyocytes determined by western 
blot in a) the right ventricle (RV), and b) the left ventricle (LV) (n = 4 each group). Data are 
given in percent (%) of the average value of the RV or LV of WT sham-operated mice. 
Densitometric analysis of NCX expression was performed and values were normalized to 
glycerinaldehyd-3 phosphate-dehydrogenase (GAPDH) expression. Representative western 
blot of c) the RV, and d) the LV. Values are depicted as mean ± SEM; analysis by two way 
ANOVA.  
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4.2.3.3. Increased MFN2 expression in RV cardiomyocytes from UCP2-/- mice after PAB 
compared to C57BL/6J (WT) mice 
MFN2 is an SR-mitochondria tether in the heart which connects the SR and mitochondria 
thereby promoting calcium exchange between both cell organelles. Expression of MFN2 was 
increased in cardiomyocytes isolated from the RV of UCP2-/- mice subjected to PAB operation 
(Figures 18a,c). No significant difference was observed in the protein level of MFN2 in LV 
cardiomyocytes from PAB-operated UCP2-/- and PAB-operated WT mice (Figures 18b,d). 
 
 
Figure 18. Expression of MFN2 in cardiomyocytes isolated from the RV and LV three 
weeks after PAB 
Mitofusin-2 (MFN2) protein expression level in cardiomyocytes determined by western blot in 
a) the right ventricle (RV), and b) the left ventricle (LV) (n = 4 each group). Data are given in 
percent (%) of the average value of the RV or LV of WT sham-operated mice. Densitometric 
analysis for MFN2 expression was performed and values were normalized to glycerinaldehyd-
3 phosphate-dehydrogenase (GAPDH) expression. Representative western blot of c) the RV, 
and d) the LV. Values are depicted as mean ± SEM; **p < 0.01 and ***p < 0.001; interaction 
between genotype and treatment was statistically significant for RV MFN2 protein expression; 
analysis by two way ANOVA.  
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4.2.3.4. Increased PLB expression in RV cardiomyocytes from UCP2-/- mice after PAB 
compared to C57BL/6J (WT) mice 
Expression of PLB showed a significant increase in cardiomyocytes isolated from the RV of 
UCP2-/- mice after PAB operation (Figures 19a,e). In cardiomyocytes isolated from the LV, no 
significant change was observed between WT and UCP2-/- mice after PAB operation (Figures 
19b,f). Amount of phosphorylated PLB compared to total PLB was unchanged between PAB- 
and sham-operated mice (Figures 19c-d, e-f).  
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Figure 19. Expression of PLB and amount of pPLB in cardiomyocytes isolated from the 
RV and LV three weeks after PAB 
Phospholamban (PLB) protein expression level in cardiomyocytes determined by western blot 
in a) the RV and b) the LV (n = 4 each group). Amount of phosphorylated phospholamban 
(pPLB) to total phospholamban (PLB)  in cardiomyocytes determined by western blot in c) the 
right ventricle (RV) and d) the left ventricle (LV) (n = 4 each group). Densitometric analysis 
for PLB expression was performed and values were normalized to glycerinaldehyd-3 
phosphate-dehydrogenase (GAPDH) expression. Amount of pPLB was normalized to amount 
of PLB protein. Representative western blot of e) the RV and f) the LV. Values are depicted as 
mean ± SEM; **p < 0.01 and ***p < 0.001; interaction between genotype and treatment was 
statistically significant for RV PLB protein expression; analysis by two way ANOVA. 
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4.2.4. The role of mitochondrial ROS and respiration  
4.2.4.1. Increased mitochondrial superoxide concentration in ISO-stimulated 
cardiomyocytes isolated from UCP2-/- mice after PAB compared to C57BL/6J (WT) mice 
To investigate the role of mitochondrial ROS in cardiomyocyte function after PAB, we 
measured mitochondrial ROS release in isolated intact cardiomyocytes. Quantification of 
MitoSOX red fluorescence after stimulation of cardiomyocytes with ISO showed higher 
mitochondrial superoxide concentration in cardiomyocytes isolated from the RV of UCP2-/- 
mice after PAB compared to WT cardiomyocytes (Figures 20a,b). Mitochondrial superoxide 
concentration in cardiomyocytes isolated from the RV of WT mice showed a decline after PAB 
compared to the sham group (Figures 20a,b). No significant change was observed in 
cardiomyocytes isolated from the LV of WT and UCP2-/- mice after PAB (Figures 21a,b). 
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Figure 20. Mitochondrial superoxide release in cardiomyocytes isolated from the RV 
three weeks after PAB 
a) Superoxide analysis as percent (%) of MitoSOX red fluorescence alteration (∆MitoSOX) 
after stimulation with 10 nmol/L isoprenaline (ISO) compared to baseline in cardiomyocytes 
isolated from the right ventricle (RV) (n = 12-18 cells each group, from at least 3 isolations). 
b) Representative images of MitoSOX staining in cardiomyocytes after stimulation with 10 
nmol/L ISO. Values are depicted as mean ± SEM; *p < 0.05 and ***p < 0.001; interaction 
between genotype and treatment was statistically significant for RV ∆MitoSOX fluorescence 
(%); analysis by two way ANOVA.  
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Figure 21. Mitochondrial superoxide release in cardiomyocytes isolated from the LV three 
weeks after PAB 
a) Superoxide analysis as percent (%) of MitoSOX fluorescence alteration (∆MitoSOX) after 
stimulation with 10 nmol/L isoprenaline (ISO) compared to baseline in cardiomyocytes isolated 
from the left ventricle (LV) without ISO stimulation (n = 40-55 cells each group, from at least 
3 isolations). b) Representative images of MitoSOX staining in cardiomyocytes after 
stimulation with 10 nmol/L ISO. Values are depicted as mean ± SEM; analysis by two way 
ANOVA. 
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4.2.4.2. Impaired cardiomyocyte function after ROS inhibition  
In order to prove the relevance of ROS for cardiomyocyte function, we measured 
cardiomyocyte contraction in presence of the superoxide scavenger tempol in isolated and 
cultured rat cardiomyocytes. Fractional shorting was decreased and the time to 50% of peak 
contraction value was increased in the presence of tempol (Figures 22a,b), while contraction 
and relaxation velocity were unchanged (Figures 22c,d).  
* Tempol studies were performed by AG Schlüter, Physiology Institute, Justus-Liebig-University, 
Giessen 
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Figure 22. Cardiomyocyte function in the presence of tempol 
Ratio of cell length shortening to diastolic cell length (dL/L) as percent (%) in isolated and 
cultured rat cardiomyocytes after treatment with 1 mmol/L tempol for 24 hrs (n = 45 cells each 
group, from at least 3 isolations), b) calcium time to 50% of peak in cardiomyocytes (n = 36 
cells each group, from at least 3 isolations), c) contraction velocity (n = 45 cells each group, 
from at least 3 isolations), and d) relaxation velocity (n = 45 cells each group, from at least 3 
isolations) in µm/s. Values are depicted as mean ± SEM;*p < 0.05 and ***p < 0.001; analysis 
by Student’s t-Test. 
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4.2.4.3. Unchanged mitochondrial respiration in permeabilized muscle fibers independent 
of the genotype and treatment  
Respiration of cardiac muscle fibers is shown in the presence of the mitochondrial 
substrates/inhibitors: pyruvate, ADP, malate/glutamate, octanoylcarnitine, succinate and 
Antimycin A. No significant alteration was observed in any group, neither in the RV nor the 
LV (Figures 23a,b). 
 
 
Figure 23. Respiratory data from cardiac muscle fibers of the RV and LV three weeks 
after PAB 
Oxygen consumption in permeabilized muscle fibers from a) the right ventricle (RV), and b) 
the left ventricle (LV) after treatment with pyruvate, ADP, malate/glutamate, octanoylcarnitine, 
and succinate corrected for oxygen consumption in presence of antimycin A (n = 3-6 each 
group). Values are depicted as mean ± SEM; analysis by two way ANOVA. 
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4.3. Expression of UCP3 in C57BL/6J (WT) and UCP2-/- mice  
In order to understand if there is a relation between UCP2 and UCP3 expression, UCP3 gene 
and protein expression was investigated in WT and UCP2-/- mice. Downregulation of UCP2 
was not associated with compensatory upregulation of UCP3. 
 
Figure 24. Relative UCP3 gene and protein regulation in the RV and LV 
Uncoupling protein 3 (UCP3) mRNA expression in the right ventricle (RV) and left ventricle 
(LV) (n = 3 each group) compared to expression of the house-keeping gene hypoxanthine 
phosphoribosyltransferase (HPRT), b) UCP3 protein expression in the RV and LV 
homogenates compared to expression of α-tubulin (n = 3 each group). Values are depicted as 
mean ± SEM. Analysis by two way ANOVA.
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5. Discussion 
Since physicians recognized the risks of PH and associated RVF 30 years ago, research focusing 
on the right heart has become more important. RVF is a common result of severe PH and the 
major cause of death in pulmonary vascular hypertensive diseases [1, 177]. Additionally, it has 
been shown that patients suffering from the left heart insufficiency have worse prognosis, if RV 
function is also compromised [1]. Although RV dysfunction plays an important prognostic role 
in PH patients, there are relatively few data on the mechanisms of chronic RV dysfunction and 
failure despite considerable research efforts [9, 178, 179]. Compared to treatment options for 
LV dysfunction, there is a lack of therapeutic options specifically targeting RV function. 
Here we demonstrate for the first time, that the lack of the mitochondrial protein UCP2 has a 
protective effect on pressure overload-induced RV dysfunction. This conclusion is based on our 
findings that RV systolic and global function was preserved in vivo in UCP2-/- mice after PAB 
operation, compared to WT mice. In vitro experiments with cardiomyocytes isolated from 
UCP2-/- mice demonstrated better contraction and relaxation properties compared to 
cardiomyocytes isolated from WT mice after PAB. 
Lack of UCP2 improved RV function and cardiomyocyte performance after PAB operation 
UCP2 is an inner membrane mitochondrial carrier protein expressed in the mammalian heart 
under normal conditions. The exact molecular function of UCP2 is unknown, but it has been 
postulated to cover a number of cellular processes including regulation of mitochondrial 
calcium, attenuation of ROS release, uncoupling function, elevated fatty acid oxidation, 
increased glutamine oxidation  and negative regulation of pyruvate uptake for respiration [104, 
105, 118, 180, 181].  
The role of UCP2 in mitochondrial Ca2+ regulation and the exact mechanism by which 
mitochondrial Ca2+ controls E-C coupling in the heart are still obscure. It has been shown that 
UCP2 overexpression in neonatal cardiomyocytes impaired E-C coupling by decreasing 
[Ca2+]m uptake, altering beat-to-beat [Ca
2+]c handling, and thus interfering with calcium-
induced calcium release from the SR [182]. Conversely, a trend towards a diminished peak 
[Ca2+]c transient was observed in isolated cardiomyocytes from UCP2 deficient mice which 
results in reduction of mitochondrial Ca2+ transients in cardiomyocytes [117]. Elevated UCP2 
expression has also been shown to protect neonatal rat ventricular cardiomyocytes from cell 
death by attenuating mitochondrial Ca2+ overload which is an important trigger of apoptosis 
[183]. However, the essential role of UCP2 for mitochondrial Ca2+ uptake has recently been 
challenged [117, 180]. The work of Motloch et al supports the concept, that cardiac UCP2 
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through interaction with other components of the calcium signalling complex indirectly 
modulates Ca2+ transport across the IMM [117]. The claim that UCP2 has regulatory function 
in Ca2+ uptake, but does not directly participate in calcium flux across the mitochondrial 
membrane, could be substantiated as the mitochondria in UCP2 KO mice are still able to take 
up Ca2+ normally [184]. These findings support a modulating role for UCP2 in mitochondrial 
Ca2+ uptake, Ca2+ handling and Ca2+ dynamic in the heart, although the molecular mechanism 
remains unclear. 
Regulation of ATP synthesis has also been postulated as another possible function of UCP2 
[181, 185]. As energy balance plays a crucial role in heart function, many studies focused on 
this aspect of UCP2. In heart failure, increased UCP2 levels led to less efficient ATP synthesis 
and thus further promoting the progression of heart failure due to increased uncoupling [185]. 
In a mouse model of aortic regurgitation, UCP2-induced ATP deficiency has been shown as a 
predominant cause of heart failure [186]. Moreover, upregulated UCP2 expression in pressure 
overload-induced heart failure by constriction of the abdominal aorta in rats was associated 
with decreased ATP levels [187]. However in another study, elevated UCP2 expression resulted 
in no significant alteration of total cellular ATP levels [182]. Contrary to these findings, 
deficiency of UCP2 attenuated right heart hypertrophy in the murine model of TAC which 
supports the hypothesis that UCP2 suppression was protective probably due to decreased 
myocyte apoptosis and increased ATP production [188].  
The beneficial role of UCP2 via decreasing cellular ROS has been proposed by several studies. 
The respiratory chain generates ROS which are well known to induce cytosolic and 
mitochondrial Ca2+ signalling, followed by the deterioration of mitochondrial function [189]. 
In the failing heart, increased oxidative stress produces mitochondrial damage, which results in 
a further production of ROS from multiple sources and this finally creates a vicious cycle of 
oxidative stress and energetic decline [189]. Of note, UCP2 affects ROS production by 
dissipating the electrochemical gradient. It was shown that UCP2 plays a protective role in heart 
failure as UCP2 overexpression attenuated the detrimental effects of ROS on cardiomyocyte 
cell death and left heart function via inhibition of mitochondrial death pathway [183]. In this 
work, Teshima et al showed that overexpression of UCP2 resulted in an attenuated degree of 
superoxide generation following prolonged exposure to H2O2, and thus decreased apoptosis in 
rat neonatal cardiac myocytes [183]. Another study also demonstrated that increased UCP2 
expression protects LV cardiomyocytes against oxidative stress and ischemia reperfusion injury 
through modulating ROS generation [190]. The importance of UCP2 in protecting against 
exogenous oxidant stress and the doxorubicin-induced cardiotoxicity was also reported by 
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Bugger et al [191]. In contrast, we demonstrate that ISO-stimulated cardiomyocytes from PAB 
UCP2-/- mice have increased mitochondrial superoxide concentration compared to WT mice 
which was associated with preserved RV function. The observed increase in mitochondrial 
superoxide production induced by β-adrenergic stimulation might be a direct effect of activation 
of the cAMP–PKA signalling pathway or it could be a consequence of the increased Ca2+ 
transients in the presence of β-adrenergic stimulation [192]. Therefore, UCP2 can potentially 
play a major role in the failing heart, based on the fact that the failing heart is challenged by 
enhanced oxidative stress. It is still a matter of debate under which conditions and by which 
mechanism, UCP2 and the regulation of ROS levels would be protective in the development of 
heart failure. Moreover, ROS may activate proliferative pathways and thus promote adaptive 
RVH [193]. 
In summary, the above studies show that UCP2 may have either deleterious or protective effects 
on right heart function during development of right heart hypertrophy and failure. The reported 
decreased ATP production due to overexpression of UCP2 may promote the transition from 
heart hypertrophy to failure [186, 187]. Calcium studies show controversial findings, but the 
protective effects in UCP2 deficient mice may be based on improved mitochondrial calcium 
buffering which results in diminished intracellular diastolic calcium content and more efficient 
E-C coupling. However, UCP2, which is involved in a negative feedback loop to inhibit 
mitochondrial ROS production, also may be beneficial in heart failure as it allows the RV to 
maintain in a fully compensated state. In our study, the sustained RV function in UCP2 deficient 
mice after PAB is in line with the findings showing beneficial effects of decreased UCP2 
expression. Our finding suggest that deficiency of UCP2 might be protective by preserving 
cardiac function in the setting of PAB-induced RVH. 
The observed discrepancies in the studies may be partly explained by the differences in animal 
models of heart hypertrophy/failure in combination with species-specific UCP2 expression 
pattern [194]. Furthermore, studies focussing on either adaptive or maladaptive forms of heart 
hypertrophy might be responsible for some of these controversies. The differences in the 
embryological origin of the RV and LV may result in controversial findings with regard to 
studies comparing RV and LV [194]. 
The expression level and effect of UCP2 may be influenced by the stage of heart failure, severity 
of disease, and animal model. Furthermore, UCP2 function might be species-specific. 
Particularly, increased UCP2 expression appears to occur mostly in end stage of left heart 
failure [194]. Chronic left heart failure resulted in elevated myocardial UCP2 expression has 
Discussion 
 
115 
  
been linked to myocardial energy deficiency [195]. In hypoxia-induced RVH, increased UCP2 
mRNA expression suggested a probable role for UCP2 in right heart remodelling as well as 
contractile function [92]. Furthermore, elevated cardiomyocyte apoptosis is observed only prior 
to UCP2 upregulation in a model of pressure overload-induced LVH which proposes regulatory 
effect of UCP2 in the stage of transition from cardiac hypertrophy to cardiac failure [196]. In 
rats with severe aortic regurgitation, UCP2 was initially decreased, but later in the course of the 
disease increased significantly compared to sham-operated rats [186]. In our study, the 
functional improvements in UCP2 KO mice are observed 3 weeks after operation which is 
shown an optimal time point for development of right heart hypertrophy in the PAB model. In 
summary, different animal models and species as well as the stage of heart failure differentially 
alter the expression of UCP2 in the heart.  
The clinical utility of TAPSE and RV Tei index for evaluation of RV function and in the 
prediction of an adverse outcome in cardiac failure has been shown as a helpful approach in 
animal studies and therefore were analysed in this study too. Our finding showed increased 
RVH in both WT and UCP2-/- mice after PAB operation. However, RV longitudinal systolic 
function, represented by TAPSE, and RV global function represented by Tei index, were 
preserved in UCP2 deficient mice. Furthermore, RV inner diameter in our findings was less 
increased in UCP2 deficient mice after PAB operation compared to WT mice indicating less 
RV dilation in UCP2-/- mice. Our findings provide evidence that UCP2-/- mice have better 
functional adaptation to increased pressure overload compared to WT mice, thus protecting the 
UCP2-/- mice from progression towards RVF.   
Interestingly, in line with our previously published work, parameters of RV function in UCP2-
/- mice were slightly decreased under basal condition compared to WT mice [119]. Such 
modification in RV function may be caused by long-term maladaptation to slightly increased 
RV afterload, as UCP2-/- mice exhibit mild PH under basal condition [119]. Moreover, effects 
of UCP2 on RV function may depend on the type and magnitude of the pressure overload and 
stage of heart hypertrophy, so that UCP2 may play a beneficial role in milder PH induced by 
CH exposure and it has deleterious effects in severe pressure overload induced by PAB.   
Due to the observed improvement in RV function independently from cardiomyocyte 
hypertrophy (indicated by unchanged heart ratio), we focused in our research on functional 
assessment of cardiomyocytes. Our study showed that PAB operation could cause an increase 
in fractional shortening in RV-isolated cardiomyocytes from both WT and KO mice under basal 
condition. This increase was even more in RV- isolated cardiomyocytes from UCP2 deficient 
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mice after PAB operation compared to sham-operated mice under stimulation with ISO. In WT 
mice, fractional shortening of myocytes remained unchanged under stimulation after PAB 
operation which shows that WT cardiomyocytes could not further augment this parameter of 
cell contractility. We could conclude that after PAB operation UCP2 deficiency potentiated the 
β-adrenoceptor-dependent cell shortening. In cardiomyocytes isolated from the LV, UCP2 
deficient mice showed increased fractional shortening after sham and PAB operation compared 
to WT mice. This effect suggests that UCP2 deficiency also plays an important role for LV 
function, as has been shown in previous studies [188]. We could also demonstrate increased 
contraction velocity and relaxation velocity in cardiomyocytes isolated from the RV of UCP2-
/- mice after PAB operation compared to cardiomyocytes isolated from the RV of WT mice after 
PAB operation under stimulation with ISO. PAB operation by itself resulted in an increased 
contraction velocity and relaxation in myocytes from RV under basal condition while after 
stimulation with ISO, PAB conferred no further augmentation for WT animals most probably 
because their myofibrils are already at maximum contraction rate with ISO. In UCP2 deficient 
mice under stimulation, the contraction velocity and relaxation velocity of cardiomyocytes from 
RV could be augmented by PAB operation as probably the myofibrils still did not reach their 
maximum contraction rate with ISO or the UCP2-/- cardiomyocytes show different response to 
β-adrenergic stimulation. The underlying mechanisms could be increased Ca2+ storage, Ca2+ 
release, and Ca2+ re-uptake by SR in UCP2-/- cardiomyocytes after PAB operation or e.g. 
different density of β-adrenoceptors. No effect of PAB on basal contraction velocity and 
relaxation velocity is observed in cardiac myocytes from the LV. PAB revealed augmented 
contraction velocity in LV-isolated myocytes from WT mice after stimulation. Cells from 
UCP2-/- mice showed augmented contraction velocity and relaxation velocity after β-adrenergic 
stimulation in both sham and PAB conditions which was almost equivalent to cells from WT 
mice.  
The contractile profile of the myocytes was increased in RV-isolated cardiomyocytes from WT 
mice after PAB operation while the CO which represents the global heart function is decreased 
in these mice. The CO is determined by the pulmonary PVR and RV contractility. Despite the 
increased contraction of the isolated cardiomyocytes which can cause increased RV 
contractility, obviously the increased afterload of the RV could not be compensated. This would 
be described as a "decoupled" state which claims that the right ventriculo-arterial decoupling 
limits the CO adaptation to increased afterload [197]. As several components are involved in 
regulation of calcium flux in myocytes, further investigation of a few major calcium signalling 
components was done in this study. 
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Improved intracellular systolic calcium increase and diastolic calcium decrease in myocytes 
from UCP2-/- after PAB operation correlated to altered SERCA2a expression  
First we set out to test whether increased contraction and relaxation of UCP2-/- cardiomyocytes 
were correlated with altered calcium flux. In the absence of myofilament properties alteration, 
the main determinant for reduced cardiac contraction of the LV is decreased cytosolic calcium 
release from the SR Ca2+ into the cytoplasm mediated by the cardiac RyR channels [198]. As 
SR Ca2+ load is a key factor in determining the amount of SR Ca2+ release, besides the disturbed 
SR calcium release via RyR2 channels, low SR calcium content itself can be the underlying 
cause of deteriorated E-C coupling and subsequent failed myocyte contraction. Treatment of 
mice with ryanodine, an inhibitor of the SR Ca2+ release, resulted in cardiac hypertrophy and 
contractile dysfunction in mice [199]. A hallmark feature of altered systolic performance in the 
failing left heart is reduced SR Ca2+ load and impaired SR function [151]. In cardiac failure, the 
inability to increase contractility during physiologic stress is consistently associated with 
reduced SR Ca2+ load [200]. Decrease in SR Ca2+ content and release has been shown in end-
stage failing LV human myocardium [201]. In failing human hearts, both [Ca2+]i transients and 
SR Ca2+ release are significantly reduced. Thus altered Ca2+ homeostasis is the result of the 
decreased capacity of the SR to accumulate Ca2+ [201]. Furthermore, reduced peak systolic 
Ca2+, increased Ca2+ transient duration and prolonged Ca2+ transient decay time have also been 
shown in myocytes isolated from failing left hearts [202, 203]. These observations indicate that 
decreased systolic Ca2+ transient amplitude secondary to reduced SR Ca2+ load is responsible 
for decreased cardiac contractility and reduced CO [202, 203]. 
Our findings demonstrated the [Ca2+]i transients were increased in RV cardiomyocytes from 
UCP2-/- mice after PAB operation. Increased [Ca2+]i transient depicts the elevated [Ca
2+]i  
released from internal Ca2+ stores and/or elevated Ca2+ entered to the cardiomyocyte which is 
in accordance with increased contractile velocity in these myocytes. The shortened time of Ca2+ 
to reach 50% of its basal value in the RV cardiomyocytes from UCP2-/- mice after PAB 
operation also demonstrates the faster removal of Ca2+ from cytosol to SR by calcium channels 
mostly SERCA2a or RyR which is in accordance with relaxation velocity results in these 
cardiomyocytes. A tendency to increased [Ca2+]i transients was also observed in RV 
cardiomyocytes from WT mice after PAB operation which was not significant. A tendency to 
increased contraction velocity was observed in these cardiomyocytes while the relaxation 
velocity did not show a tendency to increase. 
One of the factors determining SR calcium content is calcium reuptake into the SR via the PLB 
regulated SERCA2a protein. SERCA2a activity determines the rate of calcium extrusion from 
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the cytosol and diastolic function [198]. The reduced SR Ca2+ content in LVF may be due to 
decreased Ca2+ pumping by SERCA2a or increased SR Ca2+ leak via RyR2 channels [204]. In 
left heart failure, decreased and prolonged calcium transients, declined calcium load of the SR 
with concomitant diastolic calcium overload of the cytosol as well as reduced SERCA2a protein 
levels have been identified as pivotal mechanisms in progression of heart failure [205, 206]. 
Furthermore, downregulated SERCA2a and hypophosphorylated PLB were shown associated 
with impaired SR Ca2+ reuptake that in concert with leaky RyR2 channels to deplete SR Ca
2+ 
load contribute to development of heart failure [207]. In a MCT model of compensated right 
heart hypertrophy, it was proposed that increased levels of SERCA2a and decreased levels of 
total PLB, which inhibits SERCA2a, contributed to enhanced RV systolic function [208]. 
However, contrary to the above studies Kogler et al in another MCT- pressure overload study 
found that both SERCA2a and PLB were downregulated [209]. Decreased levels of SERCA2a 
were shown correlated to the degree of pressure overload and severity of RV dysfunction in a 
PAB model of RVF; while PLB remained unchanged [136]. In a feline model of pressure 
overload, severe compensated hypertrophy and heart failure secondary to pressure overload 
were accompanied by a significant decrease in SERCA abundance and activity which resulted 
in impaired contractile reserve and reduced ability to load the SR with Ca2+ [200]. Moreover, 
depletion of SERCA2 protein and subsequent decrease in its overall activity below a critical 
threshold, were shown to contribute to the onset and progression of heart failure [210]. In our 
PAB model, the protein level of SERCA2a and PLB were increased in cardiomyocytes isolated 
from the RV in UCP2-/- mice. No difference was observed in the protein level of SERCA2a and 
PLB in cardiomyocytes isolated from the LV. Moreover, no difference was seen in the ratio of 
pPLB to PLB in cardiomyocytes isolated from both RV and LV after PAB operation. SERCA2a 
plays an important role for sustained cardiomyocyte function and its increased expression in 
myocytes isolated from UCP2-/- mice after PAB operation is in line with enhanced cardiac 
contraction and relaxation observed in these cells. Paralleled by increased SERCA2a 
expression, the expression of PLB as SERCA2a-associated protein should have been elevated 
in order to make the inhibitory interaction of PLB on SERCA2a possible. The phosphorylated 
form of PLB lacks the inhibitory effect on SERCA2a and the unchanged ratio of pPLB to PLB 
makes the inhibitory effect of PLB on SERCA2a possible. Thus, UCP2-/- has an effect on 
SERCA2a on the expression level, but not on functional level via the ratio of pPLB/PLB. 
Novel approaches, utilizing SERCA2a gene therapy to directly target calcium physiology in 
heart failure pathologies have recently been highlighted. In animal models of LVF, gene 
transfer of SERCA2a improved cardiac hemodynamics and cardiac contractility, and thus 
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resulted in increased survival [211-214]. Moreover, SERCA2a gene transfer restored the 
oxygen consumption of the LV to the normal level which signifies an improvement in cardiac 
energy utilization [212]. However, overexpression of SERCA2a in rats increased the 
occurrence of fatal ventricular tachyarrhythmia following infarct, which may be caused by 
adverse electrical remodelling due to reduced NCX expression and function triggered by 
elevated SR Ca2+ load [215]. Altogether, these findings suggest that targeting SERCA2a 
therapeutically in cardiac failure might be beneficial under certain conditions. 
Based on the current state of research, similar pathomechanisms may underly the dysfunctional 
calcium handling in right and left heart failure, although the adaption process may differ. 
Moreover, no regional differences between cardiomyocytes isolated from the RV and the LV 
could be detected in regard to SR calcium uptake and expression of components of the calcium 
handling system [216]. Interestingly, we found unaltered expression level of SERCA2a in the 
cardiomyocytes from LV after PAB operation and no difference was observed between WT 
and UCP2-/- mice, although the cardiomyocytes from LV in UCP2-/- mice already showed 
increased dl/L% after PAB operation. This discrepancy cannot be explained and needs to be 
further investigated. 
 In line with our findings, downregulation of genes involved in the maintenance of Ca2+ 
homeostasis has been shown in RV myocardium of rats with right heart failure, whereas no 
changes in the expression levels of these genes were found in LV myocardium [209]. 
In accordance with the previously described pivotal role of SERCA2a in left heart failure and 
the potential to improve cardiac function by overexpression of SERCA2a [206], in this study 
we observed increased cytosolic calcium transients and faster removal of calcium in UCP2-/- 
cardiomyocytes after PAB operation compared to WT cardiomyocytes. These findings helped 
us to identify increased SERCA2a protein level as underlying mechanism contributing to 
cardiac functional alterations, indicating a similar mechanism as in left heart dysfunction. As 
SERCA2a and the plasmalemmal protein NCX compete for the transport of [Ca2+]i and thus 
determine the amount of Ca2+ available for release by the SR upon the next contraction, we also 
investigated the NCX protein expression, but could find no changes. Increased NCX function 
can compete with SERCA2a during [Ca2+]i decline, extruding more Ca
2+ from the cell and 
depleting the SR. Our finding of unchanged NCX could be interpreted that the regulation of 
NCX expression in this experimental model is not sensitive to pressure overload and Ca2+ 
homeostasis is regulated by intracellular sources, but not Ca2+ influx through the plasmalemmal 
membrane. This interpretation is in line with  the observation that in LV cells of mice and rats, 
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calcium is removed by SERCA ten times more effectively than by NCX [198]. Of note, NCX 
function is dependent not only on its expression, but also on local Na+ and Ca2+ levels and 
action potential configuration – all of which are altered differently depending on the underlying 
pathophysiology [217]. Furthermore, cardiac wall stress is a major determinant for the 
expression of the SERCA whereas NCX may be expressed independently from it [218]. Patients 
with end stage of heart failure showed higher expression of NCX protein and mRNA [219, 
220]. However, as no significant correlation between NCX mRNA and the clinical stage of 
heart failure was observed in humans, NCX mRNA level seems not suitable as a marker for 
myocardial dysfunction [221]. Interestingly, in patients with cardiac failure, impaired diastolic 
function was associated with decreased SERCA2a and unchanged NCX, whereas increased 
expression of the NCX was associated with preserved diastolic function. One can speculate that 
an increase in protein levels of NCX protein represents an important mechanism regulating 
diastolic calcium elimination and diastolic function in the failing human myocardium [222]. 
Decreased NCX to SERCA ratio in a feline LV failure model resulted in improved basal 
myocyte contractility and decreased rest decay which supports the hypothesis that contractile 
myocyte behaviour is influenced by the balanced SERCA and the NCX activity [223]. In our 
study, the expression level of NCX remained unchanged after PAB operation in cardiomyocytes 
from both WT and UCP2 deficient mice. The expression and function of the NCX in 
hypertrophy and heart failure are still controversial.  It should be mentioned that heart failure is 
a complex and heterogenous disease and relative contributions of SERCA2a and NCX probably 
vary in different disease models, origins and stages of heart failure. 
SR calcium dynamics may be altered by increased physically tethering of the SR and 
mitochondria via increased expression of the mitochondrial protein MFN2 which thereby 
creates putative microdomains that forces mitochondrial uptake of calcium released by the SR 
[224, 225]. In this study we could observe increased MFN2 expression in cardiomyoctes from 
UCP2-/- mice after PAB operation. In accordance to our observation, MFN2 deficient mice 
displayed slight heart hypertrophy and dysfunction [101]. Downregulated MFN2 expression 
was demonstrated in hypertrophied intact hearts and cultured myocytes and indicates that 
MFN2 expression levels are dependent of both the etiology and the time course of hypertrophy 
[152]. However, we can only speculate that these alterations are induced directly by UCP2 and 
lead to improved calcium handling and are not caused secondarily to improved calcium 
handling.  
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UCP2 deficiency may regulate calcium dynamics and SERCA2a expression by increased 
ROS release 
We further investigated by which mechanism genetic suppression of UCP2 would result in 
increased cardiomyocytes’ calcium dynamics and SERCA2a protein expression. SERCA2a 
expression can be regulated by calcium and ROS sensitive pathways, e.g. via the p38-MAPK 
pathway and GATA [26, 134]. In this regard we could show that 1) UCP2-/- cardiomyocytes 
exhibited elevated mitochondrial superoxide concentration during ISO stimulation after PAB 
operation in comparison to WT cardiomyocytes and 2) inhibition of ROS production by the 
SOD-mimetic tempol decreased cardiomyocyte contraction and relaxation. Thus, increased 
ROS release from UCP2-/- mice after PAB may directly increase SERCA2a expression via ROS 
sensitive pathways and/or improve acutely calcium dynamics, which in turn can increase 
SERCA2a expression via calcium sensitive pathways. In this regard, it has also been shown 
that calcium signalling pathway activated by depleted SR/ER calcium and via activating 
transcription factor 6 (ATF6) modulation might lead to SERCA2a upregulation as a 
compensatory response which explains the elevated SERCA2a expression via calcium sensitive 
pathways [226]. Although the consensus is that defective Ca2+ sequestration by the SR is a 
major hallmark in the failing myocardium, there exist significant controversial reports about 
the molecular mechanisms including SERCA2a expression in different animal models and heart 
failure patients [227].Unfortunately, due to the limitation of sustaining primary isolated 
cardiomyocytes in culture, investigating long term effects of ROS inhibition on SERCA2a 
expression in adult mouse cardiomyocytes was not possible.  
It is likely that redox regulation of other Ca2+ handling components including RyR2 and PKA 
also contributes to altered Ca2+ handling and thereby elevated SERCA2a expression and would 
be a point of interest in future research. In more detail, ROS may promote cardiomyocyte 
contraction by activation of SERCA2a via oxidatively activated PKs, e.g. PKA, which its 
activation progressively removes the inhibitory influence of PLB on SERCA2a [228, 229] or 
by elevated SR calcium release via direct activation of RyR2 channels [228, 230] or by indirect 
activation via CICR by ROS promoted activation of LTCC [192]. It has been demonstrated that 
ROS may inhibit SR calcium reuptake by decreasing the activity of SERCA2a via direct 
interaction with its redox sensitive cysteine residues [231]. The differential actions of ROS may 
depend on the ROS concentration and localization. It is shown that low concentrations of ROS 
increased systolic calcium release of the SR in cardiomyocytes, while excessive ROS 
production reduced SR calcium release [143]. Also, [Ca2+]c levels and [Ca
2+]c transients of rat 
cardiomyocytes increased markedly in response to high concentration of ROS in 
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cardiomyocytes isolated from rats [232]. The reciprocal interactions between Ca2+ and ROS 
signalling systems is also dependent on the type of target proteins, the ROS species, the dose 
as well as time point [233]. Our results concentrating on the beneficial effects of ROS are in 
line with a recent study in LV cardiomyocytes demonstrating that mitochondrial ROS increased 
calcium transient amplitude and myocyte contraction after acute stimulation with ISO and that 
this effect can be inhibited by ROS scavengers [234].  Animal models of right heart hypertrophy 
demonstrated low or even decreased level of ROS in compensated right heart hypertrophy, 
while excessive ROS production promotes the transition to decompensation by influencing 
HIF-1α stabilization [36]. Interestingly, it was demonstrated that a NOX4-dependent protective 
pathway, with HIF-1α being a major driver of this process, is one of the potent redox-sensitive 
protective pathways that is activated during chronic pressure overload [235]. 
Besides ROS, UCP2-/- may increase mitochondrial respiration via an increased pyruvate 
oxidation and thus promote the energy status of the cardiomyocytes. On the other hand, loss of 
UCP2 may decrease utilization of FA for respiration [181]. It was shown that UCP2 activity 
decreased the contribution of glucose to mitochondrial oxidative metabolism and elevated 
oxidation of alternative substrates such as FAs [118]. Also UCP2 KO cells displayed a 
metabolic switch from FA oxidation to glucose metabolism indicating that UCP2 promotes 
mitochondrial FA oxidation while mitochondrial catabolism of pyruvate is limited [111]. A 
metabolic switch from mitochondrial pyruvate oxidation to anaerobic glycolysis has been also 
shown to promote RV failure [236] while decreased mitochondrial FA oxidation have been 
linked to late stages of LV failure [194]. Furthermore, dysfunctional RV hypertrophy, in the 
setting of severe PAH, is characterized by a metabolic switch from aerobic to anaerobic 
metabolism [1]. Thus, promoting glucose oxidation in disfavour of FA oxidation by UCP2-/- 
might delay RVF. However, the rate of FA oxidation was preserved or even increased in 
physiological/adaptive LVH, but it declined during the progression to decompensated heart 
failure [125]. Similar results have been reported for the non-dysfunctional, mechanically-
induced RV hypertrophy in rats with PAB, which exhibited high rates of FA oxidation [77]. 
However, in skinned muscle fibers isolated from the right heart from UCP2-/- mice, we could 
not detect any differences in pyruvate or octanoylcarnitine stimulated respiration after PAB 
operation. We also could not observe decreased respiration after PAB operation in WT mice 
compared to sham-operated mice, which has been already described in intact cardiomyocytes 
[236].  
UCP2 gene mutations, resulting in increased UCP2 expression or function, transcriptional, 
translational and protein turn-over alterations, post transcriptional modifications or hormonal, 
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nutritional and pharmacological regulation may increase the susceptibility for patients to 
develop RV failure in contrast to patients that can preserve RV function even under increased 
RV afterload. Polymorphisms of the UCP2 promoter which affect UCP2 expression have been 
described to occur e.g. in atherosclerosis, diabetic retinopathy and hypertension [237]. Thus, 
further investigation of decreased UCP2 protein or mRNA expression levels related to recently 
described genetic polymorphisms may lead to development of novel biomarkers or treatments 
in humans susceptible for development of RVF. Furthermore underlying regulatory pathways 
may be exploited to enhance RV function, e.g. by micro-RNAs or targeting the PPAR pathway 
which regulates UCP2 expression. 
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6. Conclusion 
The decompensated right heart failure is a frequent cause of death as a result of afterload by 
PH. It arises after mechanisms that lead to RVH and adaptive compensated right heart failure, 
have been exceeded. The RV is the main determinant of functional state and disease prognosis 
in PH. However, despite the impact of right heart failure, the pathogenesis is still not well 
understood.  
Experimental evidence presented in this study demonstrate that UCP2 is a novel potential 
therapeutic target which protects the RV specifically from pressure overload-induced 
dysfunction and adverse remodelling. As underlying mechanism we demonstrated improved 
cardiomyocyte contractile phenotype and calcium dynamics, presumably via upregulation of 
SERCA2a and MFN2 expression. Our observations could confirm that therapeutic strategies 
that attempt to increase SERCA2a protein expression levels may be useful for the treatment of 
pressure overload-induced right heart hypertrophy. 
However, whether increased SERCA2a expression is a direct consequence of UC2 deficiency 
or improved Ca2+ handling by UCP2 deficiency, remains unclear. Altogether, differences in the 
model of hypertrophy, extent of degree of hypertrophy and the stage of investigation could 
account for the discrepancies and inconsistencies between findings of the present thesis and 
other reports. Also, the reported differences by literature between the knockout UCP2 model 
and the UCP2 overexpression model could be interpreted that the overexpression systems might 
potentially produce an artificial biological phenomenon.  
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Figure 25.  Genetic suppression of UCP2 leads to improved contractility in PAB  
UCP2 deficient cardiomyocytes (UCP2 -/-) showed increased expression of sarco(endo)plasmic 
reticulum Ca2+-ATPase (SERCA2a), phospholamban (PLB) and mitofusin-2 (MFN2) after 
PAB. These alterations may cause improved removal of Ca2+ from the cytosol during diastole 
and subsequently enhanced release of calcium from the SR during systole. This improved Ca2+ 
handling in UCP2-/- cardiomyocytes may result in the observed improvement of relaxation and 
contraction of cardiac myofibrils after PAB and help to maintain CO in UCP2 -/- mice despite 
increased afterload. In WT mice, although the contractility of cardiomyocytes is increased after 
PAB, this increase may not be sufficient to overcome the increased afterload and result in a 
decrease of CO, a phenomenon also described as “ventricular-arterial uncoupling”.  
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7. Summary 
RVF occurs when mechanisms compensating an increased RV afterload e.g. caused by PH, 
pulmonary vascular stenosis, etc. are exhausted. We hypothesized that transition from 
compensation to decompensation of the RV may be promoted by changes in cardiomyocytes’ 
calcium dynamics, release of ROS and metabolism. Therefore, we investigated the role of 
mitochondrial uncoupling protein 2 (UCP2) in a murine model of RV hypertrophy and failure. 
Pressure overload was induced by PAB in UCP2 deficient mice (UCP2-/-) and in C57BL/6J 
mice. Three weeks after PAB or sham operation, right heart hypertrophy and function were 
determined by invasive hemodynamics and echocardiography. Contraction and relaxation of 
cardiomyocytes isolated from these mice, as well as cellular calcium dynamics and 
mitochondrial superoxide release were measured by fluorescence microscopy. Expression of 
the cardiac calcium handling proteins SERCA2a, PLB and the NCX, as well as MFN2, which 
is a mitochondrial protein that has been shown to influence mitochondrial-SR interaction, were 
determined by immunoblotting. Mitochondrial superoxide release and respiration were 
determined by the fluorescent dye MitoSOX, and high resolution respirometry, respectively. 
Echocardiographic and hemodynamic assessments revealed that: 
 PAB induced increased right ventricular systolic pressure (RVSP) in C57BL/6J and 
UCP2-/- mice 
 PAB induced right heart hypertrophy in C57BL/6J and UCP2-/- mice 
 PAB induced a decrease of CO and RV dilation as signs of RV decompensation in 
C57BL/6J mice 
  Right ventricular function was preserved after PAB in UCP2-/- mice in contrast to 
C57BL/6J mice  
Functional studies in cardiomyocytes revealed that: 
 Cardiomyocytes isolated from the RV of both, C57BL/6J and UCP2-/- mice, showed 
increased contractility, despite decrease of CO in C57BL/6J mice 
 Cardiomyocytes isolated from the RV of UCP2-/- mice showed further improved 
function after PAB compared to C57BL/6J mice 
 Cardiomyocytes isolated from the RV of UCP2-/- mice showed improved contraction 
and relaxation after PAB compared to C57BL/6J mice 
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 Analysis of calcium dynamics in isolated cardiomyocytes revealed that: 
 Calcium transients were increased in cardiomyocytes from UCP2-/- mice after PAB 
compared to C57BL/6J mice 
 The time of calcium to reach 50% of the basal value was decreased in cardiomyocytes 
from UCP2-/- mice after PAB compared to C57BL/6J mice 
Expression of calcium handling proteins in cardiomyocytes revealed that: 
 SERCA2a expression was increased in RV cardiomyocytes from UCP2-/- mice after 
PAB compared to C57BL/6J mice 
 MFN2 expression was increased in RV cardiomyocytes from UCP2-/- mice after PAB 
compared to C57BL/6J mice 
 NCX expression and PLB expression were unchanged in cardiomyocytes from UCP2-/- 
mice after PAB compared to C57BL/6J mice 
ROS studies in cardiomyocytes and mitochondrial respiration in muscle fibers revealed 
that: 
 Isolated cardiomyocytes from UCP2-/- mice after PAB showed increased mitochondrial 
superoxide concentration under stimulation compared to C57BL/6J mice 
 ROS inhibition by superoxide scavenger tempol decreased cardiomyocyte function and 
contractility 
 Mitochondrial respiration in permeabilized muscle fibers remained unchanged 
independent of genotype and treatment 
We conclude that UCP2 deficiency may protect from pressure overload-induced RV 
dysfunction via improved cardiomyocyte calcium dynamics due to increased SERCA2a 
expression. Regulation of calcium dynamics due to increased SERCA2a may be regulated by 
increased ROS release. Therefore, UCP2 deletion and SERCA2a may be considered as novel 
therapeutic targets to inhibit transition from compensated RV hypertrophy to RVF. 
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8. Zusammenfassung 
Zu einem Versagen des rechten Ventrikels (RV) kommt es, wenn das rechte Herz nicht länger 
in der Lage ist eine gesteigerte RV Nachlast, wie sie z.B. durch eine pulmonale Hypertonie oder 
eine pulmonal-vaskuläre Stenose verursacht wird, zu kompensieren.  
Das Ziel dieser Arbeit war es, zu überprüfen, welche Mechanismen für den Übergang von einer 
kompensierten zu einer dekompensierten Rechtsherzfunktion verantwortlich sind. Die 
zugrundeliegende Hypothese war, dass Änderungen in der Kalziumdynamik von 
Kardiomyozyten oder/und die Freisetzung reaktiver Sauerstoffspezies (ROS) und des zellulären 
Metabolismus verantwortlich für die Dekompensation des Herzens sind. 
Aufgrund seiner Beteiligung an den oben genannten Mechanismen sollte die Rolle des 
mitochondrialen entkoppelnden Proteins 2 (mitochondrial uncoupling protein 2, UCP2) beim 
Rechtsherzversagen in einem Mausmodell des pulmonalarteriellen bandings (PAB) untersucht 
werden. 
Zur Erzeugung eines erhöhter RV Druckes wurden sowohl UCP2-defiziente (UCP2-/-) als auch 
WT (C57BL/6J) Mäuse einer PAB- oder Sham- (gleicher Eingriff ohne Ligatur der 
Pulmonalarterie) Operation unterzogen. Drei Wochen nach der jeweiligen Operation wurde 
mittels hämodynamischer Messungen und Echokardiographie der Grad der Hypertrophie und 
die Funktion des RV untersucht. Weiterhin wurde unter Zuhilfenahme von 
Fluoreszenzmikroskopie die Kontraktion und Relaxation isolierter Kardiomyozyten sowie die 
zelluläre Kalzium-Dynamik und die mitochondriale Superoxid-Freisetzung gemessen. 
Zusätzlich wurde die Expression von Proteinen, die am Kalziumtransport der Kardiomyozyten 
beteiligt sind, der sarco endoplasmatic reticulum calcium ATPase 2a (SERCA2a), 
Phospholamban (PLB) und des sarkolemmalen Natrium-Kalzium-Austauschers (NCX), sowie 
von Mitofusin-2 (MFN2), dass auch die Interaktion von Mitochondrien und SR reguliert, in 
Kardiomyozyten anhand von Immunoblots quantifiziert. Schließlich wurde noch die 
Respiration mittels hochauflösende Respirometrie bestimmt. 
Die echokardiographischen und hämodynamischen Untersuchungen zeigten, dass 
 PAB bei C57BL/6J- und UCP2-/--Mäusen zu einer vergleichbaren Erhöhung des 
rechtsventrikulären systolischen Druck führte, 
 PAB eine rechtsventrikuläre Hypertrophie bei C57BL/6J- und UCP2-/--Mäusen 
induzierte, 
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 PAB eine Abnahme des CO und RV Dilatation, als Zeichen der RV Dekompensation 
in C57BL/6J mice induzierte und 
 die rechtsventrikuläre Funktion bei UCP2-/--Mäusen im Gegensatz zu den WT Mäusen 
erhalten blieb. 
Die funktionalen Studien an Kardiomyozyten verdeutlichten, dass 
 die Kontraktilität von isolierten Kardiomyozyten sowohl von C57BL/6J, als auch 
UCP2-/- Mäusen erhöht war, trotz einer Abnahme des CO in C57BL/6J Mäusen, 
 die Funktion, Kontraktion und Relaxation der isolierten RV Kardiomyozyten von 
UCP2-/--Mäusen nach PAB besser war als die der Kardiomyozyten von C57BL/6J-
Mäusen. 
Die Analyse der Kalzium-Dynamik in isolierten Kardiomyozyten wiesen daraufhin, dass 
 die Kalziumströme der Kardiomyozyten von UCP2-/--Mäusen nach PAB gesteigert 
waren verglichen mit denen von C57BL/6J-Mäusen, 
 bei UCP2-/--Mäusen die Halbwertszeit bis zum Erreichen von 50% des Kalzium-
Grundwertes kürzer war als die der C57BL/6J-Mäuse. 
Die Expression der Kalzium-transportierenden Proteine in den Kardiomyozyten zeigte, 
dass 
 nach PAB die Expression von SERCA2a, MFN2 und PLB in den RV Kardiomyozyten 
der UCP2-/--Mäuse erhöht war verglichen mit der Expression der C57BL/6J-Mäusen, 
 die Expression von NCX in den Kardiomyozyten der UCP2-/-- und  C57BL/6J-Mäusen 
nach PAB nicht unterscheidbar war.  
Die Untersuchungen zur ROS-Freisetzung in Kardiomyozyten und zur mitochondrialen 
Respiration in Muskelfasern ergaben, dass  
 isolierte Kardiomyozyten der UCP2-/--Mäuse nach PAB bei Stimulation eine erhöhte 
mitochondriale Superoxid-Konzentration aufwiesen als die der C57BL/6J-Mäuse, 
 eine ROS-Inhibition durch den Superoxid-Fänger Tempol die Funktion und 
Kontraktilität der Kardiomyozyten beeinträchtigte, 
 sich die mitochondriale Respiration permeabilisierter Muskelfasern unabhängig von 
Genotyp und Behandlung nicht veränderte. 
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Die Ergebnisse dieser Arbeit zeigen, dass eine Deletion des UCP2-vor einer RV Dysfunktion 
hervorgerufen durch eine erhöhte Nachlast schützt, indem es aufgrund einer gesteigerten 
SERCA2a-Expression zu einer verbesserten Kalzium-Dynamik der Kardiomyozyten führt. 
Diese Regulierung der Kalzium-Dynamik wird vermutlich durch eine erhöhte ROS-Freisetzung 
hervorgerufen. Aus diesen Gründen handelt es sich bei SERCA2a und UCP2 um potentielle 
neue Ziele für die Therapie der maladativen Rechtsherzhypertrophie. 
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